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The overall aims of this research were to develop and evaluate a method for 
Drug Utilisation Review in a primary health care setting. More specifically, 
it was to evaluate the use of antihypertensive drugs and their medical and 
socioeconomic consequences in the Mamre community. 
One hundred and ninety five residents, 35 years or older, known to be on 
antihypertensive treatment for more than three months, participated in the 
study. The data were collected in two phases. The first involved the 
administration of a questionnaire by trained interviewers and the second 
involved the review of the patients medical records. The questionnaire was 
divided into 3 sections:-
1. to obtain background information and particulars of the participants and 
the prescribers 
2. to obtain information on all medicines taken by the participants and the 
type of medical facility they attended 
3. to obtain information on the impact of antihypertensive drugs on the 
participants' social well being, their financial burden and the 
perceived side effects experienced as a result of these agents. 
Analysis of the results showed that the average hypertensive patient in the 
Mamre community was female (73.8%), with a standard 5 or 6 education and was 
59 years old. They usually had one or more of the following concomitant 
diseases; gout or rheumatic conditions, diabetes and heart problems. 
Approximately 70% of the participants attended state run medical facilities 
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(district surgeons, day hospitals and teaching hospitals). Nearly a quarter of 
the participants attended more than one medical facility. 
A total of twenty-seven different drugs were taken by the study participants 
for their hypertension but 61.5% of them were receiving only one drug. 
Approximately 70% of the participants were estimated to be compliant or 
probably compliant with their antihypertensive treatment. Eighty five percent 
of the participants perceived themselves to feel better on their treatment and 
88% were satisfied with their medical care. 
Approximately 24% of the study participants were in paid employment. While 40% 
of the participants were responsible for payment for their visit and 
medicines, 75% of these attended one of the state facilities. About half of 
the participants who had to pay for their treatment themselves could not 
afford to. The participants attending the state facilities either paid nothing 
or had to pay themselves. The mean cost of a doctors visit to a state facility 
was R3.00, while the mean cost of the medicines was R7.12. Participants who 
attended private doctors either paid for their own treatment or it was paid 
for by a third party (eg. medical aid, employer). The mean cost of a visit to 
a private doctor was R9.14 and the mean cost for medicines was R41.00. 
The dose of the antihypertensive drugs were found to be correct 70% of the 
time. Thirty six percent of the participants stood a theoretical chance of 
experiencing a drug interaction if they were taking more than one drug. Side 
effects were reported to be experienced by just over 40% of the participants. 
xi 
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It is assumed that these adverse effects were not very severe, as only five 
participants stopped taking their medicine as a result. Assuming that the 
original diagnosis of hypertension was correct, the study found that blood 
pressure was adequately controlled in nearly 50% of all the study 
participants. 
Antihypertensive drug treatment in the Mamre community was mostly 
appropriately used and controlled 60% of those participants whose blood 
pressure readings were available from their doctors records, without 
intolerable side effects. Their treatment did not appear to impact to any 
great extent on their quality of life, but did appear to be a significant 
financial burden for those participants who had to pay for their treatment. 
A method was therefore developed whereby a sample of patients with a specific 
disease state from a specific community was identified. Data on drug 
utilisation were obtained through review of the patient records and structured 
interviews and the medical, social and economic outcomes of the drugs• use 
were obtained. 
This method and its shortcomings were critically examined. In the process 
useful data on the utilisation of antihypertensive in the "real life" primary 




In order to form the best possible sociomedical and health economic 
basis from which regulatory and other decisions can be made, audit 
systems need to be established. In principle such audit systems involve 
a number of sequential steps. The first is the collection and 
compilation of the relevant facts; the second involves organisation and 
analysis of the data; the next step centers around what decision are to 
be made and subsequently their implementation. The final step is one of 
re-evaluation, with appropriate adjustments if required (Knoben, 1981). 
These types of audits have been termed Drug Utilisation Review studies 
and serve as a quality assurance process, which in turn promotes 
rational drug use. Appropriate Drug Utilisation studies are invaluable 
tools for all involved in drug and health policies and related decision 
making. They also represent a mechanism for improved communication 
between health authorities, health personnel and scientists. However, 
functional systems for conducting such reviews are still lacking in most 
countries, a situation which could lead to the danger that many 
important decisions are made arbitrarily and that their consequences are 
rarely known (Baksaas, 1986). South Africa is no exception to this 
finding. A recent survey of South African hospitals revealed that only 
12% had quality review committees (Summers, 1991) and no such community-
based studies could be found in the recent literature. 
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The expansion of the Pharmaceutical industry since the late 1950 1 s and the 
resultant plethora of new drug products on the market has created concern for 
iatrogenic disease associated with drug use (Hutchinson et al, 1990), as well 
as inappropriate drug use. As a result, the need for rationalising drug 
therapy became an emerging issue. More recently, the cost associated with drug 
therapy and in particular irrational drug use has added an important new 
dimension to the clinical decision-making process. 
One area in which there has been a surge of new drugs is that of hypertension. 
These newer agents, such as the ACE-inhibitors and calcium channel blockers, 
are considerably more expensive than the older agents (thiazide diuretics, 
reserpine and beta-blockers). These agents have been widely promoted as having 
comparatively less adverse effects and thereby giving a potentially higher 
quality of life (Croog et al, 1986). There is, however, still some controversy 
as to the cost-benefit ratio of these agents, especially when used to treat 
mild hypertension (Johannesson et al, 1992; Kawachi, 1992). On the other hand, 
what are the costs of the side effects and the reportedly poor metabolic 
profiles of the older agents? Optimal management of hypertension therefore 
involves finding a balance among its benefits, risks and costs, while ensuring 
that the adverse effects of the drugs do not compromise patient compliance. 
In South Africa, very little is known about the patients' perception of their 
antihypertensive drug treatment and of the socioeconomic consequences of such 
treatment. These factors, together with the medical outcomes, form the 
complete picture of the consequences of treatment for the patient. Before any 
definitive guidelines can be developed for the management of hypertension in 
2 
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South Africa, it is imperative that such information is available. It is with 
this objective in mind that this study was undertaken. Furthermore, it is 
anticipated that the methodological issues clarified by doing this study will 
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1. DEFINITION 
The World Health Organisation (WHO) defines Drug Utilisation as the 
marketing, distribution, prescription and use of drugs in society with 
special emphasis on the resulting medical, social and economic 
consequences (Grimsson, 1980). This definition does not limit drug 
utilisation to merely detecting adverse reactions, but extends it to 
drug efficacy and gives the social and economic consequences equal 
importance to the medical consequences (Grimmson, 1980). The definition 
also recognizes that several steps and factors are involved in the drug 
use process, and that in each of these steps problems in drug use can 
arise. Factors that may contribute to these problems can have 
historical, social, organisational, political, economic, technologic, 
psychologic or pharmacologic origins (Serradell et al, 1987). At the 
moment drug utilisation studies do not cover the broad definition. As 
early as 1982 Friebel reported that, a decade after this shortcoming was 
described, drug utilisation studies still deal mainly with the 
prescription patterns and touch only briefly on the other questions 
(Friebel, 1982). 
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2. DIFFERENCES IN PRESCRIBING PATTERNS 
There is an increasing awareness of the fact that available drugs are 
not always used in the best possible way and that there are large 
differences in the prescribing patterns in the different regions of the 
same country (Gross, 1975). These differences generally lack rational 
explanations. Because of large differences in the prescribing and small 
explanations, it appears important to study these differences and their 
possible outcomes (Hjort et al, 1984). The large differences in the drug 
utilisation patterns between doctors, hospitals, regions and countries 
can be, in a small part, accounted for by the differences between 
individual doctors, hospitals and medical schools. What is observed, 
however, are large differences and small explanations, (Hjort et al, 
1984) especially in the view of the fact that doctors have the 
opportunity to contact one another and exchange opinions through 
journals, congresses and symposia (Gatti, 1975). 
3. THE ECONOMIC CONSEQUENCES OF DRUG USE 
The medical consequences of prescribing differences are probably small 
but they have important economic implications (Hjort et al, 1984) 
especially in todays health services where money matters. The cost 
impact of drugs must not be defined too narrowly, so as to only include 
the acquisition cost of the drug. Also to be considered are the costs 
associated with physician visits, laboratory tests and treatment of drug 
6 
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induced side effects (Anderson et al, 1990). There is increasing 
pressure on doctors to use the cheapest drug available, unless it can be 
proven that the more expensive one gives better results. While this may 
take away the room for both doctor and patient individualisation, it 
will leave less room for irrational prescribing (Hjort et al, 1984). 
However, policies that encourage the use of drugs carrying the lowest 
price tag may not always result in the lowest overall health care cost 
(Anderson et al, 1990). 
Compounding the problem of the spiralling cost of medicines , is the 
ever increasing speed and number of new drugs which are appearing on the 
market (Hitchinson et al, 1990) and the societies 1 belief that there is 
now 11 a pill for every ill. 11 In this drug-minded world over-prescribing 
of drugs is unavoidable, the consequences of which may not be harmful in 
relation to more or less inactive drugs, but becomes more serious when 
trivial symptoms or diseases are treated with highly active remedies, 
the use of which should be limited to the established indication (Gross, 
1975). A large number of prescriptions are useless, they do not help the 
patient, but fortunately they do not harm him either, because the human 
organism tolerates a lot (Gross, 1975). Nevertheless senseless 
prescribing is not what medicine is aiming at and should be reduced as 
much as possible (Gross, 1975). Studies have shown that not all 
prescribing is based on the patients needs and not all patients needs 
are met by drug therapy (Serradell et al, 1987). 
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The high cost of medicines and the potential for unwanted reactions 
require health care professionals to be extremely proficient in their 
ability to use drug therapy rationally (Hutchinson et al, 1990). If the 
over-riding goal of health care is to improve the health status, then it 
follows that every health care policy and program must be evaluated in 
terms of the patients• health status (their quantity and quality of 
life, their ability to perform personal, occupational and social roles 
and the burden of physical and psychological symptoms). Drugs through 
their direct pharmacologic effects can influence health status (Anderson 
et al, 1990). Drug therapy should therefore be monitored for 
effectiveness and adverse effects. Inappropriate medication may lead to 
prolonged illness and increased costs (Natiello, 1988). Cost reductions 
should be accomplished without an unacceptable decline in health status 
of the population affected (Anderson et al, 1990). 
4. THE OBJECTIVE OF A DRUG AUDIT 
The objectives of a drug audit is to identify problems associated with 
prescribing and to provide recommendations that lead to solutions for 
the identified problems (Serradell et al, 1987). The theoretical purpose 
of implementing a program of drug use review, as stated by the U.S. Task 
Force on prescription drugs, is to establish a dynamic review process 
aimed firstly at rational prescribing, (the right drug, for the right 
patient, in the right amounts, at the right time) with the consequent 
improvement in the quality of care, and secondly at minimizing needless 
expenditure (Knoben, 1981). 
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Blood pressure control and the pathophysiology of hypertension 
THE NORMAL PHYSIOLOGY OF THE BLOOD PRESSURE REGULATING 
SYSTEMS IN THE BODY 
Blood pressure is the pressure of the column of circulating blood within the 
vascular system (Macdonald Critchely, 1980). The term 11 blood pressure 11 implies 
the systemic arterial pressure. Many organs and factors are responsible for 
normal regulation of blood pressure. The organs involved include amongst 
others the sympathetic nervous system, kidneys and adrenals (Kochar et al, 
1979), while the major factors involved are the pumping action of the heart, 
the viscosity of the blood, the total length of the resistance vessels, the 
amount of blood in the system and the elasticity of the arterial walls (Kelly 
et al, 1989). These factors are summarised by the hydraulic equation; arterial 
blood pressure is directly proportionate to the product of the blood flow 
(cardiac output, CO) and the resistance to passage of blood through 
precapillary arterioles (peripheral vascular resistance, PVR) (Katzung, 1989). 
BP= CO x PVR 
The pressure in the aorta and in the brachial and other large arteries in a 
young adult rises to a peak value (systolic pressure) of about 120 mmHg during 
each heart cycle and falls to a minimum value (diastolic pressure) of about 70 
mmHg (Ganong, 1991). Increases in cardiac output, which are determined by the 
heart rate and stroke volume (amount of blood ejected from the heart per beat) 
generally result in a raised systolic blood pressure. Diastolic blood 
pressure, on the otherhand, is influenced by the resistance in the arterioles. 
The arterioles have a rich supply of sympathetic nerves containing 
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norepinephrine, which when released act on the smooth muscle cells causing 
vasoconstriction. Renin, secreted from the kidneys, results in the production 
of angiotensin II which is a potent vasoconstrictor (Fox et al, 1986; Kochar 
et al, 1979). 
Physiologically, in both normal and hypertensive individuals, blood pressure 
is maintained by moment-to-moment regulation of cardiac output and peripheral 
vascular resistance. The renal and adrenal cortical mechanisms help in the 
long-range maintenance of normal blood pressure (Katzung, 1989). Baroreflexes 
act in combination with humoral mechanisms and the renin-angiotensin-
aldosterone system, as well as other mechanisms, to coordinate function at 
these control sites and to maintain normal blood pressure. Regulation of blood 
pressure in hypertensives differs from normotensives in that the baroreceptors 
and the renal blood volume pressure control systems appear to be 11 set 11 at a 
higher level of blood pressure. 
11 
tpter 2. Blood pressure control and the pathophysiology of hypertension 
1.1. SHORT TERM BLOOD PRESSURE CONTROL 
Baroreflexes are responsible for the rapid, moment-to-moment, short term 
adjustments of blood pressure (Katzung, 1989). With increasing age and with 
increasing levels of resting, mean arterial blood pressure, however, there is a 
marked decrease in baroreflex sensitivity (Sleight, 1986). The internal pressure 
of the blood against the vessel wall stretches the vessel wall, which in turn 
stimulates the carotid baroreflexes. Activation of baroreceptors inhibits 
central sympathetic discharge, whereas reduction in stretch results in a 
decrease in baroreceptor firing. When sympathetic discharge is disinhibited the 
reflex acts through sympathetic nerve endings to constrict the arterioles, 
therefore peripheral vascular resistance and cardiac output are increased and 
blood pressure is restored to normal or increases (Katzung, 1989). 
The autonomic nervous system (ANS), comprising the sympathetic and 
parasympathetic systems, plays a dominant role in blood pressure regulation. 
Increased sympathetic stimulation leads to an increased release of 
catecholamines (adrenaline and nor-adrenaline) which in turn increases the heart 
rate and force of contraction of the heart (beta-adrenergic receptors) and also 
causes constriction of the peripheral arterioles (alpha-adrenergic receptors), 
while parasympathetic stimulation decreases the heart rate (Paton, 1984; Kochar, 
1978). Alpha-1 receptors are located on blood vessels and cause 
vasoconstriction, while beta-1 receptors are located on the heart and cause an 
increase in the heart rate as well as an increase in the force of myocardial 
contraction. The release of noradrenaline therefore results in a rise in blood 
pressure. Most catecholamines released from the nerve terminals are reabsorbed 
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and less than 5% are absorbed into the blood and finally excreted in the urine 
(Sleight, 1986). Despite the large reuptake of noradrenaline, studies have shown 
that under the same conditions at rest there is a direct correlation between 
plasma noradrenaline concentrations and the level of diastolic blood pressure 
(Kiowski et al, 1981; Engelman et al, 1970; Buhler et al, 1980). 
1.2. LONG TERM BLOOD PRESSURE CONTROL 
The kidney is primarily responsible for long term blood pressure maintenance by 
regulating the fluid and electolyte balance of the body, thereby homeostatically 
regulating the extracellular fluid volume (Katzung, 1989). If the arterial blood 
pressure rises, the kidney excretes more salt and water until it reaches 
equilibrium at the original blood pressure. Moreover they produce vasoactive 
substances, kinins and prostaglandins, which are thought to have a local 
vasodilator action (Buhler et al, 1983). Sodium depletion, hypovolaemia, 
sympathetic neural activity (via beta-adenoreceptors) and the secretion of 
catecholamines stimulates the kidney to secrete renin. Alteration in tubular 
fluid composition and vascular stretch also stimulates the production of renin 
(Katzung, 1989; Kochar, 1978). Renin is responsible for the formation of 
angiotensin I which is converted to angiotensin II. Angiotensin II is a potent 
arteriolar vasoconstrictor. In addition, angiotensin II stimulates the 
sympathetic nervous system and promotes the synthesis of aldosterone in the 
adrenal cortex. Aldosterone acts primarily at the distal tubule and collecting 
ducts of the nephron where it enhances sodium absorption and potassium 
excretion. Sodium retention leads to the expansion of extracelluler volume and 
elevation in blood pressure. The resultant increase in blood pressure and 
therefore pressure natruresis has a twofold effect reducing renin release again 
13 
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and restoring sodium/volume homeostasis (Buhler et al, 1983). In the 
hypertensive patient, pressure naturesis is impaired and blood pressure seems to 
rise to a point where the sodium balance is restored. There does, however, 
appear to be a sub-group of patients with essential hypertension who have an 
inherited or acquired inability of the kidney to handle sodium loads (Stokes GS, 
1988). 
1.2.1. Renin status of patients with essential hypertension 
Radioimmunoassays of the various intermediates of the renin system allow for 
patients to be classified into high, normal and low renin groups (Brunner et al, 
1972). Analysis of the renin status of patients with essential hypertension 
classifies 15% as high renin, 55 - 65% as normal renin, and 20 - 30% as low 
renin. (Williams, 1991; Laragh, 1980). With increasing age, plasma angiotensin 
II levels fall and the percentage of patients with high renin levels decline, 
and the percentage of patients with low renin levels increase (Tuck et al, 
1973). 
Low-renin essential hypertension occurs more frequently in black patients and 
in older patients (Williams, 1991; Birkenhager et al, 1976). These patients are 
shown to have an expanded extracellular fluid volume, but are not neccessarily 
hypokalaemic. Involvement of the adrenal cortex in low-renin hypertension, is 
suggested by the observation that large doses of mineralocorticoid antagonists 
(eg. spironalactone) and inhibition of steroidgenesis by aminoglutethimide can 
result in sodium loss and the lowering of blood pressure in these patients. It 
has also been postulated that these patients have an increased sensitivity of 
14 
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their adrenal cortex to angiotensin II (Williams, 1991). The fact that low-renin 
hypertensive patients are significantly older (aproximately 9 years) than 
patients in the other two sub-groups, even though they often have higher blood 
pressures, suggests that they enjoy some measure of protection from 
cardiovascular damage, namely atherosclerotic diseases eg. ischaemic heart 
disease, peripheral vascular disease and cerebrovascular disease (Laragh, 1980). 
In high-renin essential hypertension it is suggested that the elevated renin 
levels and blood pressure, may both be secondary to an increased activity of the 
adrenergic system (Willliams, 1991). High renin essential hypertension is often 
termed angiotensin dependant hypertension. These patients are often younger with 
greater variability of blood pressure, heart rate and cardiac output (Burkart et 
al, 1976). 
1.3. CARDIAC OUTPUT AND ARTERIOLAR RESISTANCE 
Reactive hypertrophy of the myocardium and of the vascular smooth muscle occurs 
as a function of blood pressure elevation and time. This becomes an important 
homeostatic mechanism for helping to maintain the blood pressure in all forms of 
hypertension (Stokes GS, 1988). Vascular smooth muscle hypertrophy may occur in 
part because of a disturbance of cell growth, contingent upon primary changes in 
cell membrane function (sodium-hydrogen countertransport) in essential 
hypertension (Lever AF, 1986). Changes in cell membrane cation transport in 
essential hypertension have also been postulated to lead to increased vascular 
smooth muscle contractility by increasing intracellular calcium concentration 
(Stokes GS, 1988). 
15 
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2. THE PATHOPHYSIOLOGY OF HYPERTENSION 
2.1. CLASSIFICATION OF HYPERTENSION 
High blood pressure is not clearly defined. Arbitrary levels have been 
established to define those who have an increased risk of developing a morbid 
cardiovascular event and/or will clearly benefit from medical therapy 
(Willliams, 1991). The Heart Foundation of South Africa suggested that 
hypertension in adults of any age is defined as a persistently elevated systolic 
blood pressure of more than 160 mmHg and/ or a diastolic pressure of more than 
95 mmHg (Heart Foundation, 1992). 
2.1.1. Essential Hypertension 
"Essential hypertension" is defined as blood pressure elevation stemming from a 
progressive rise in pressure with age for which there is no obvious cause 
(Beilin L, 1989). This definition is correct for 95% of cases of so-called 
hypertension. 
(i) Malignant Hypertension:-
refers to a patient in which the blood pressure suddenly rises, and the 
disease accelerates from its slowly progressive form (Sleight P, 1986). 
This increase is accompanied by papilloedema, usually retinal 
haemorrhages and exudates, proteinuria, haematuria and progressively 
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destroyed by fibrinoid necrosis, and such patients usually have diastolic 
pressures of 120 mmHg or above. 
(ii) Accelerated Hypertension:-
signifies a significant recent increase over previous hypertensive levels 
associated with evidence of vascular damage on funduscopic examination but 
without papilloedema. 
(iii) Sustained Hypertension:-
is thought to result from the 11 resetting 11 of the carotid sinus 
baroreceptors so that the homeostatic mechanism tends to maintain rather 
than combat increased arterial pressure. 
(iv) Rebound Hypertension:-
is a syndrome which follows the abrupt withdrawal of certain types of 
antihypertensive treatment such as clonidine and the beta-adrenergic 
antagonists (Robertson et al, 1986). 
Secondary Hypertension 
Patients with a specific organ defect responsible for hypertension are said to 
have secondary hypertension (Williams, 1991). Nearly all the secondary forms are 
related to primary aldosteronism, Cushing 1 s syndrome, pheochromocytoma, 
exogenous hormones eg. oral contraceptive pills and/or renal function. These 
cases comprise no more than 10% of the hypertension present in the Westernised 
communities (Stokes,G.S. 1988). 
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1. INTRODUCTION 
The cause of essential hypertension is multifactorial (Beilin,L. 1989). 
Factors such as obesity, alcohol consumption, diet and physical inactivity 
play a major part in the elevation of blood pressure, each operating against a 
background of varying genetic susceptibility. These variables in addition to 
the level of arterial pressure per se modify the course (Wilson JD et al, 
1991). Thus, the risk of developing a morbid cardiovascular event with a given 
arterial pressure may vary by as much as twentyfold depending on whether 
associated risk factors are present (Wilson JD et al, 1991). 
Hypertension is one of several risk factors for cardiovascular disease and 
should always be assessed and treated in the context of the other existing 
risk factors. 
2. HEREDITY 
Genetic factors have long been assumed to be important in the genesis of 
hypertension (Wilson JD et al, 1991). Data supporting this view can be found 
in both animal as well as population studies in humans. Hypertension tends to 
run in families (Pickering, 1968) and studies of identical twins in different 
environments support this fact (Miall, 1963). 
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3. STRESS 
Despite the extensive literature on psychological factors, it is still not 
clear whether they play a significant part in the long-term blood pressure 
regulation, though there is no doubt that the emotional factors can induce 
pronounced but transient variations in blood pressure (Beilin L. 1989). 
The influence of stress due to urbanisation is difficult to separate from the 
influence of increased dietary salt intake and the adoption of a western diet. 
4. SALT 
Dietary sodium intake of most developed countries varies from 100 -300 
mmol/person/day, which is in excess of normal physiological requirements 
(Beilin L, 1989). Randomised controlled trials of the effects of sodium 
restriction to 70 -90 mmol/day suggest significant blood pressure reductions 
of the order of 3 -5 mmHg systolic pressure in hypertensives. The blood 
pressure reduction is most clear cut in older subjects, in patients with 
moderate or severe hypertension and salt reduction increases the effectiveness 
of most other antihypertensive drugs, for example, diuretics and angiotensin 
converting enzyme inhibitors (Swales JD, 1989; Beilin L, 1989). Levels of 
dietary sodium and potassium are generally inversely related, as populations 
with high salt intake tend to eat little in the way of fruit and vegetables 
(Beilin L, 1989). Cross-sectional population studies suggest that dietary 
potassium has a blood pressure lowering effect, and that estimates of dietary 
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sodium:potassium ratios are more strongly associated with blood pressure 
levels than their cations independently. 
5. OBESITY 
There is a continuous linear relationship between excess body fat, blood 
pressure levels and the prevalence of hypertension (Messerli F.H., 1986). An 
increase in body mass requires an increase in cardiac output and intravascular 
volume to fulfil metabolic requirements. This increase, however, exceeds by 
far the amount needed to perfuse excessive adipose and supportive tissue. The 
effect of obesity on blood pressure appears to be additive to that of alcohol 
consumption, and may be compounded by physical inactivity and specific dietary 
components, such as high salt intake (Beilin L, 1989). As obesity also 
contributes to blood lipids abnormalities and impaired glucose tolerance, it 
has particular significance as a factor underlying the increased prevalence of 
coronary artery disease in hypertensive patients. A weight loss of 3 kg 
reduces blood pressure by approximately 7 mmHg systolic/4mmHg diastolic and a 
weight loss of 12 kg gives a fall of 21/13 mmHg (Swales J.D. 1989). 
6 . AGE AND SEX 
Elderly hypertensive patients are usually characterised by a low cardiac 
output and, as a consequence, by a very high total peripheral resistance 
(Messerli F.H., 1986). In the elderly, the left ventricle is burdened with a 
high afterload which accelerates the age-induced decline of left ventricular 
performance. The more severe the arterial hypertension, the faster left 
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ventricular function declines and the earlier the stage of congestive heart 
failure will be reached. At the same time, renal blood flow often falls even 
faster than systemic blood flow because of progressive nephrosclerosis. In 
parallel with the increase in total peripheral resistance, intravascular 
volume becomes more and more contracted. This volume contraction makes elderly 
hypertensive patients particularly susceptible to volume depletion. 
Circulating noradrenaline levels are usually elevated, whereas plasma renin 
activity has been shown to be low and less responsive in elderly hypertensive 
patients, unless congestive heart failure is present. Except for some 
primitive societies, hypertension is extremely common in the elderly and a 
disproportionate rise in systolic pressure with age is usual so that isolated 
hypertension is quite common (Kannel WB. 1986). Whatever the variety of 
hypertension in the elderly, it is clearly dangerous from the standpoint of 
absolute risk, risk gradients and attributable risks. Cardiovascular mortality 
is tripled in the hypertensive elderly compared to normotensives of the same 
age (Kannel WB, 1986). 
Blood pressure in women rises with age but at a lower level than 
men until the menopause, when it reaches the male level (Stokes, 
1988). Despite this factor there is no evidence that women 
tolerate hypertension well at any age (Kannel, 1986). 
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7. RACE 
Hypertension is more prevalent in blacks than whites, and systemic vascular 
and target organ disease such as hypertensive heart disease, stroke and 
nephrosclerosis is also more rapid and severe (Messerli F.H., 1986). However 
there is not a significant difference in cardiac output, total peripheral 
resistance or intravascular volume between blacks and whites with essential 
hypertension. On studying renal and hepatic blood flow, it was found that 
hepatic blood flow was similar in blacks and whites, but renal blood flow was 
lower and renal vascular resistance was higher at any level of renal arterial 
pressure in blacks. Black patients also had increased left ventricular mass 
when compared with white patients that were matched with regard to mean 
arterial pressure (Masserli FH, 1986). 
8. EXERCISE 
There is good evidence that regular physical exercise may reduce blood 
pressure substantially (Swales JD, 1989). Individuals who undertake regular 
physical exercise have lower blood pressures than sedentary people (Beilin L, 
1989). 
9. SMOKING 
Smoking does not itself lead to hypertension but it greatly increases the 
vascular complication rate in people with hypertension (Simpson FO, 1988). The 
MRC Working Party (UK, 1985) and the Australian National blood Pressure Study 
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(1980) showed very clearly that in very mild hypertension the benefits of not 
smoking are greater than those of antihypertensive drug treatment. The risks 
carried by a hypertensive patient who smokes are additive to the risk of 
hypertension (Swales J.D. 1989). Smoking leads to an acute elevation of blood 
pressure, though the effect usually subsides within 15 minutes of finishing a 
cigarette unless combined with strong coffee, when it may persist for up to 2 
hours (Beilin L, 1989). Regular smokers tend to have a slightly lower blood 
pressure than non smokers, largely because they tend to be slimmer. 
Unfortunately, the small potential benefit of this effect is greatly 
outweighed by the adverse effects of smoking on coronary heart disease and 
other pathologies (Beilin L, 1989). 
10. ALCOHOL 
Alcohol has recently emerged as another major contributor to blood pressure 
elevation (Beilin L, 1989). The relationship appears to be linear above 10 -
20g ethanol equivalent per day. (i.e. 1-3 standard drinks per day) (Editorial; 
Annals of Int. Med., 1986). People who have three or more standard drinks per 
day have a threefold increased prevalence of mild hypertension compared with 
non-drinkers. Reducing alcohol intake by 80% can result in a significant and 
reversible fall in blood pressure within 1-2 weeks. There is no justification 
for advising moderate drinkers to abstain totally (Swales JD, 1989). 
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11. BLOOD LIPIDS 
The lipoproteins play a central role in the atherosclerotic process 
accelerated by hypertension (Kannel WB, 1986). The well established positive 
relation of the serum total cholesterol to coronary heart disease incidence is 
now recognised as a direct consequence of the low density lipoprotein (LDL) 
cholesterol component. The high density lipoprotein (HDL) cholesterol fraction 
involved in removal of cholesterol from the tissues has been shown to be 
inversely related to the occurrence of coronary heart disease. It was 
originally thought that the VLDL (very low density lipoprotein) cholesterol 
did not contribute to artherogenesis (Kannel, 1986), but patients with high 
VLDL may infact have increased risk for premature atherosclerosis when 
associated with other risk factors for coronary artery disease, such as 
diabetes, smoking and hypertension (Wilson, 1991). 
12. IMPAIRED GLUCOSE TOLERANCE 
Diabetes is often associated with a poor cardiovascular risk profile including 
blood pressure, reduced HDL cholesterol and obesity (Kannel WB, 1986). The 
risk of coronary heart disease in hypertensives is enhanced by diabetes, and 
the risk of every clinical manifestation of the disease is greater in the 
diabetic hypertensive than in the non-diabetic. The relative impact is greater 
in women than men. Diabetes also directly damages the myocardium so that 
hypertensive cardiac failure is more likely to occur than in the non-diabetic 
with hypertension (Kannel WB, 1986). 
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13. INSULIN RESISTANCE 
Insulin resistance is generally interpreted as the physiological state under 
which insulin causes a reduced glucose lowering effect, while 
hyperinsulinaemia is considered to be a result of insulin resistance (Baba T & 
Neugebauer, 1994). The aetiology of resistance to insulin-stimulated glucose 
uptake is unknown, although it is probably under genetic control (Ferrannini & 
Defronzo, 1989). Insulin is thought to raise the blood pressure by a few 
possible mechanisms (eg. stimulating sympathetic nervous system activity and 
enhancing renal tubular sodium reabsorption)(Young JB, 1988; Treisan Met al, 
1988). On the other hand insulin has been reported to possess a vasodilatory 
property (Hall JE et al, 1990). Neither an insulin infusion within a 
physiological range nor continuously sustained hyperinsulinaemia in patients 
with insulinaemia are associated with elevated blood pressure. The 
relationship between insulin and blood pressure is therefore still under 
discussion, and there seems to be insufficient evidence to prove that insulin 
per se can raise blood pressure in humans (Baba T & Neugebauer S, 1994). 
However, epidemiological evidence suggests a link between hypertension, 
diabetes, adiposity and an abnormal lipid profile and that the prevalence of 
each disease increases with age (Ferrannini et al, 1990; Reaven GM & Hoffman 
BB, 1987), referred to as syndrome X. Age has been suggested to parallel a 
decrease in the whole body insulin-stimulated uptake of glucose (De Franza RA, 
1981). Obesity studies have suggested that the peripheral insulin sensitivity 
is decreased by up to 30 - 40% in individuals with more than 130 -140% of 
ideal body weight and in nondiabetic individuals who gained their weight by an 
excessive caloric intake (Ferrannini E & De Franza RA, 1989). 
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1. PREVALENCE RATES IN SOUTH AFRICA. 
Hypertension remains a major health concern in the industrialised world and 
much of the third world. Persons with hypertension are at excessive risk for 
cardiovascular disease, coronary heart disease, congestive heart failure and 
renal failure. The prevalence of hypertension varies widely around the world 
and these differences can be attributed in part to environmental differences 
including life style (Grimm, 1991). 
Epidemiological studies in South Africa suggest that hypertension, where blood 
pressure is greater than or equal to 160/95mmHg, is common among urbanised 
South Africans or those who follow a typical westernised lifestyle (Steyn, 
1991). On the basis of the 1991 Census it was estimated that approximately 6,5 
million South Africans have a blood pressure above 140/95mmHg and 
approximately 3,2 million have a blood pressure above 160/95mmHg (Heart 
Foundation, 1992). The prevalence of hypertension differs in the various 
population groups of Southern Africa. In the urban zulu it has been quoted as 
high as 25% compared with 10% in the rural zulu. In urban Indians it is 19%, 
in the urban whites 23% and in the rural whites 26%. The presence in the urban 
coloured population is 28% (Steyn et al, 1990). Various epidemiological 
studies in South Africa have confirmed that hypertension is inadequately 
diagnosed and treated, suggesting the need for improved population based 
management in South Africa (Steyn, 1991). 
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2. THE AIM OF HYPERTENSION TREATMENT 
In the vast majority of cases the cause of hypertension is still not known, 
but in about 5-10% of cases hypertension is secondary to some known 
pathological condition or drug induced (Seedat,1991). All other patients have 
essential or primary hypertension - a persistently raised blood pressure with 
no underlying cause (Kendle, 1989; Seedat, 1991). A persistent elevation of 
blood pressure above 90-95mmHg for diastolic pressure, is found to be 
associated with an increase in cardiovascular morbidity and mortality (Venter, 
1990), therefore the basic principle of drug treatment is to lower the 
patient 1 s blood pressure to an acceptable level with the minimum interference 
to his or her well being. However, there are no studies that show a beneficial 
effect of drug treatment if the initial DBPwas less than 105 mmHg. The aim of 
antihypertensive treatment is to obtain normotension and to reduce 
cardiovascular risk, thereby preventing coronary heart disease, stroke and 
death. The clinical end point is the regression of the left ventricular mass, 
the prevention of renal damage and of retinal haemorrhages (Nieminen, 1991). 
3. MANAGEMENT OF HYPERTENSION 
There are two modes of treatment which must be combined; non drug treatment 
and drug treatment. Non-pharmacological methods may be used as sole treatment 
for borderline or mild elevation of blood pressure or as an adjunct to 
pharmacological therapy. These measures involve weight reduction, alcohol and 
smoking cessation, reduction of salt intake and the promotion of exercise 
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(Hansson et al, 1990). Drug treatment of patients whose diastolic blood 
pressure dose not exceed lOOmmHg is likely to cause more problems than 
benefits, unless there are secondary factors to consider such as diabetes or 
hyperlipidaemia (Hepburn et al, 1990). 
4 . WHEN TO START DRUG TREATMENT 
It is advocated that hypertension should ideally be detected as early as 
possible and treated aggressively to avoid target organ damage and all its 
consequences (Venter, 1990). Non drug treatment is indicated for the total 
population whatever the blood pressure (except the rare person with 
pathological hypotension). It is more difficult, however, to decide when to 
start drug treatment. It will probably vary according to factors such as age, 
sex, population group and other cardiovascular risk factors. South African 
Hypertension Society suggest that in South Africa it would be appropriate to 
start non drug treatment if the diastolic blood pressure was 95mmHg or greater 
and only to initiate drug treatment if there were co-existing risk factors for 
cardiac disease or if no response is obtained from non drug treatment after 3-
6 months. Non pharmacological measures should be maintained, in addition to 
drug treatment (Heart Foundation Concensus, 1992). The British Hypertension 
Society's recommendations are not to initiate drug therapy unless the 
diastolic blood pressure is greater than or equal to lOOmmHg and the patient 
has other risk factors for vascular disease (British Hypertension Society 
Working Party, 1989). The American Joint National Committee on hypertension 
recommend an intermediate position of 95mmHg for diastolic blood pressure 
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(Joint National Committee on Detection, Evaluation and Treatment of High Blood 
Pressure, 1988). There is reasonable consensus that antihypertensive drugs 
should be given to patients up to the age of about 75-89 years if their 
diastolic pressure is consistently over 95-lOOmmHg for a period of four months 
(Hansson et al, 1990). The South African Hypertension Concensus Document 
recommends non-pharmacological management for all patients with a blood 
pressure above 140/95 and drug plus non-drug treatment for those with a blood 
pressure above 160/95 and evidence of end-organ damage or coexisting risk 
factors. The goal blood pressure should be the same as that for initiation of 
treatment, however, if there is evidence of end-organ damage or other 
coexisting risk factors for cardiovascular disease then the goal blood 
pressure should be <140/90mmHg, irrespective of the baseline blood pressure 
level (Heart Foundation, 1992). It has been suggested that the lowering of 
diastolic blood pressure below 85mmHg predisposes patients with ischaemic 
heart disease to myocardial infarction, though the evidence for this is still 
controversial (Swales, 1989; Fletcher et al, 1991). Isolated systolic 
hypertension is initially treated non-pharmacologically, however, when the 
systolic blood pressure is consistently 160mmHg or greater and the diastolic 
pressure is less than 90mmHg, despite non-drug measures, then antihypertensive 
drug treatment should be considered (Seedat, 1991). 
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5. COMPLIANCE PROBLEMS 
Lowering of the blood pressure by using pharmacological agents is not an 
innocuous procedure and may even have serious consequences on the mortality 
and morbidity, if not done discreetly and carefully (Venter, 1990). Probably 
the most difficult aspect of long term antihypertensive therapy is that while 
the disease is relatively asymptomatic, the adverse effects of therapeutic 
lowering of blood pressure with drugs are numerous, often requiring an 
alteration of the patients life style (Morse et al, 1986). The adverse effects 
may influence the quality of life to such an extent that the treatment of 
hypertension may be worse than the disease and its consequences and it may 
thus have negative effects on compliance (Venter, 1990). 
6. REDUCTION OF MORBIDITY AND MORTALITY DUE TO TREATMENT 
Seftel asks the question of why we consider treating mild hypertension and in 
doing so transform a mass of people into patients with all its physical, 
psychological, social and economic implications (Seftel, 1991)? The answer 
lies in the fact that most trials have clearly been shown to reduce 
cardiovascular morbidity and mortality. A 40-50% reduction in stroke has been 
demonstrated, but unfortunately very little effect on coronary heart disease 
was noted (Hansson et al, 1990). A recent meta-analysis of the drug trials in 
hypertension indicated that 5-6mmHg reduction in diastolic blood pressure, 
maintained for a few years, produced a 14% reduction in coronary events 
(expected 20-25%). Mac Mohan et al calculated that a lOmmHg lowering of 
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diastolic blood pressure was associated with at least 56% less stroke and 37% 
less coronary heart disease (Mac Mohan et al, 1990). On the other hand the 
British Medical Research Council (MRC) trial suggested that 850 low risk 
patients would have to be treated for one year to prevent one stroke (MRC 
Working Party, 1985) and the Australian National Blood Pressure Survey showed 
a saving of two lives per 1 000 patient years of treatment (Louis, 1991). 
7. ANTIHYPERTENSIVE COMPOUNDS SUITABLE FOR INITIAL THERAPY 
The fact that not all patients respond equally well to all antihypertensive 
drugs and the introduction of the calcium channel antagonists and the 
angiotensin converting enzyme (ACE) inhibitors have challenged the rigid 
11 stepped-care 11 approach for drug treatment of hypertension. Four groups of 
antihypertensive drugs are regarded as equally suitable for the first step of 
antihypertensive therapy: angiotensin converting enzyme inhibitors, beta-
blockers, calcium antagonists and diuretics. This view is supported by 
recommendations from the Joint National Committee (JNC) in the USA, the World 
Health Organisation and the International Society of hypertension (Hansson et 
al, 1990). The South African Hypertension Society finds the recommendations of 
the JNC generally applicable to the local situation, but stresses that the 
cost of treatment should also be considered together with the patient as a 
whole in their social setting (Heart Foundation, 1992). Patients should 
ideally start with a single drug in the smallest effective dosage. Combination 
therapy is indicated if monotherapy fails, as most antihypertensive drugs act 
synergistically and frequently counter each others unwanted effects (Venter, 
33 
hapter 4. The problems of hypertension and the treatment of hypertension 
1990). All classes contain extremely useful drugs which benefit individual 
groups of patien\s and have all been shown to be efficacious. Once the blood 
pressure has been normal for a year or more, a cautious decrease in 
antihypertensive drug dosage and renewed attention to non-pharmacologic 
treatment may be worth trying (Abramowicz, 1989). 
There remain however many areas of controversy in the treatment of 
uncomplicated essential hypertension. Some trials have suggested that 
diuretics may actually increase the infarction and sudden death rates in 
hypertensives due to their effect on blood electrolytes and lipids (Raftrey, 
1991). Given the large differences in the cost of treatment with different 
classes of antihypertensives, an assessment of factors such as cost 
effectiveness and quality·of life parameters becomes essential. A question 
that therefore needs elucidation is if treatment with the more expensive 
agents (eg. ACE inhibitors) is associated with tangible differences in these 
factors and more specifically should they replace traditional agents such as 
the thiazide diuretics as first line therapy in the average case of 
uncomplicated hypertension (Louis, 1991). 
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1. INTRODUCTION 
There are many practical problems in the treatment of hypertension, namely to 
get the right patient under treatment and then to treat them properly. 
Furthermore, little is known about the behavior and ideas of patients and 
practitioners which can profoundly influence the treatment and therefore the 
control of hypertension. 
2. FACTORS ASSOCIATED WITH THE PATIENT 
Patient factors such as age, sex, race, weight, renal function, pregnancy, 
mental status and attitude towards the disease may all be important variables 
to consider in selecting drug therapy as this may reveal how a patient will 
comply with the therapy (Stewart, 1981). Most patients do not have perfect 
compliance and take about 70-80% of their prescribed treatment, with 
compliance improving immediately before a clinic visit - the so called 
11 toothbrush effect 11 (Pullar et al, 1990). Non-compliance with prescribed 
medication regimens is a major problem, especially in the management of 
chronic disease states such as hypertension, where the disease is manifest by 
symptoms or is often symptomless (Stewart, 1981). Inadequate compliance may 
lead to treatment failure, which is obviously of great importance and even 
potentially fatal for the individual. The reasons for poor compliance could be 
that patients do not understand the instructions, that they forget to take 
their treatment or that they have made a decision not to do so. This may be 
related to factors such as complex drug regimens, (eg. multiple medication use 
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and frequent dose regimens) poor packaging of the drug or inadequate advice on 
the importance of compliance with the drugs. The conscious decision not to 
take the prescribed medicines may be due to fear of possible adverse effects 
which the patient does not want to discuss with the physician or 
dissatisfaction with their doctor or medical service (Pullar et al, 1990). 
Lastly the cost of hypertension treatment is not limited to drug costs, but 
also includes doctors fees, absence from work and transport costs. This cost-
benefit ratio is a critical factor in the compliance of many patients (Opie, 
1989). 
3. FACTORS ASSOCIATED WITH THE PRESCRIBER 
Physician prescribing is perceived by many patients to be the major reason for 
visiting primary care doctors (Anderson et al, 1990). Physicians• diagnostic 
and therapeutic skills will be major determinants as to whether the correct 
drug is prescribed for the appropriate indication and in the appropriate dose 
(Stewart, 1981). Various factors such as input from the patient, commercial 
sources, colleagues, universities, academic literature and government 
regulators will influence the prescribing patterns (Soumeria et al, 1989). 
Because many of the prescription drugs commonly used today were only approved 
for use in the last 10-15 years, doctors who graduated from medical school 
before the release of these drugs may not have been exposed to formal 
education on the benefit and risks associated with these medicines. The 
pharmaceutical industry therefore plays an active role in educating the 
doctors by devoting substantial resources to informing doctors of the benefits 
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of their products (Anderson et al, 1990). A wide variety of factors may 
contribute to inappropriate prescribing decisions such as failure of doctors 
to keep abreast of developments in pharmacology, overpromotion of drugs by the 
pharmaceutical sales representatives and simple errors, oversights or 
omission. The doctors ignorance of (or apathy) towards cost issues and 
insulation of the doctor and patient from cost considerations because of third 
party coverage may further contribute to the problem. Pressure from patients, 
families or other health workers for a particular drug regardless of 
indication, overreliance on clinical experience versus scientific data, the 
doctors need to provide some treatment for problems with no clear medical 
solution and the tendency to use prescriptions as a 11 termination strategy 11 to 
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1. DESCRIPTION OF THE MAMRE COMMUNITY 
Mamre was established by the Moravian Church in 1808. It is a small 
community, of approximately 5 000 inhabitants, situated on the west coast 
48km from Cape Town. Mamre is in a state of transition and accelerated 
urbanisation caused by the encroachment of Cape Town and Atlantis (Klopper 
et al, 1988). 
Recently the Department of Community Health at the University of Cape Town 
and the Centre for Epidemiological Research (CERSA) of the Medical Research 
Council (MRC) set up a long-term community based study in this urbanising 
community with the overall aim of improving the health status of the people 
of Mamre and developing an approach to health promotion which may be 
applicable to other similar areas (Klopper et al, 1989). 
2. MORBIDITY AND MORTALITY PROFILES 
The need for quantitative information on the health status of the 
communities, their use of health services and the socioeconomic and 
environmental factors affecting health, is well recognised. Such 
information is critical for the appropriate development of health services 
and the future attainment of optimal levels of health in South Africa 
(Hoffman et al, 1988). 
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In 1986 Benatar•s report on medicine and health care in South Africa 
described the disease and mortality profile of the coloured population in 
comparison to the profile of developing countries (Benatar, 1986). Coronary 
heart disease, common among South African whites, is increasingly 
manifesting itself in the coloured community (Steyn and Fourie, 1990). 
Analysis of the mortality statistics for Mamre) from the Regional Services 
Council records) for 1981-1987 reveals that accidents or violence were the 
major cause of death. The most common natural cause of death in the 
community was circulatory disease (Bourne et al, 1988). Investigations of 
several chronic conditions for which people said that they were receiving 
treatment, yielded rates of 57/1 000 for hypertension, 29/1 000 for 
11 nerves 11 , 13/1 000 for diabetes, and 19/1 000 for tuberculosis. The fact 
that reported rates of hypertension and diabetes were low is likely to be 
due to undetected cases in the community (Hoffman et al, 1988). 
3. PREVALENCE RATES OF HYPERTENSION 
The Mamre Community Health Project presents an ideal opportunity to assess 
disease patterns and health-related issues in a well defined community. In 
a follow-up study in which women between the ages of 25 and 64 years had 
their blood pressure measured, an overall prevalence rate of 25.9% was 
found. Age specific rates were 16.1% for the 24 to 44 year group and 38.4% 
for the 44 to 64 year group (Marshall et al, 1988). The CRISIC study which 
examined blood pressure among the coloured population of Cape Town reported 
a prevalence of 18.4% for females between 15 and 64 years. When these rates 
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were adjusted against international reference populations the prevalence in 
these coloured women was found to be 26% (Steyn et al, 1986). A disturbing 
finding in the Mamre community was that despite a good overall reported 
compliance of 72.2%, more than half the subjects on treatment (54.3%) were 
inadequately controlled. One can either conclude that the medication was 
not been taken correctly or that the treatment regimens were inappropriate 
(Marshall et al, 1988). 
The findings in Mamre are in keeping with other prevalence studies in the 
coloured population, namely that the prevalence of hypertension is high and 
up to 50% of patients on treatment are inadequately controlled (Marshall et 
al, 1988). The fact that hypertension is underdiagnosed, undertreated and 
poorly controlled is characterised by the "rule of halves, 11 which states 
that:- only approximately half of hypertensives have ever been diagnosed, 
of which only half receive antihypertensive treatment and about half of 
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Chapter 7. Research definition 
1. GENERAL AIM 
To develop and evaluate a methodology for a Drug Utilisation Review in 
Primary Health Care. 
1.1. SPECIFIC AIM 
In order to achieve this general objective a pilot study was undertaken 
in the Mamre community with the following aim: 
to develop a method to evaluate the use and medical and socioeconomic 
implications of antihypertensive drug treatment in the Mamre community. 
2. OBJECTIVES 
2.1. To determine baseline data (see Appendix I) on the use of 
antihypertensive drugs in the Mamre community. 
2.2. To establish background data on both the patients and the 
prescribers. 
2.3. To compare the data on the use of antihypertensive drugs in the 
study population against the predetermined explicit criteria 
(Appendix I, 7). 
2.4. To assess the medical and socioeconomic consequences of the use of 
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To assess the number of hypertensive patients in the sample 
population whose blood pressures are controlled on their 
medication. 
To identify known side effects of antihypertensive drug 
treatment that are most troublesome to the study population. 
To obtain an approximate estimation of the patients reported 
compliance on their treatment. 
To assess the patients attitude towards their 
antihypertensive drug treatment. 
To obtain a measure of the patients perception of the 
influence of their antihypertensive medicine on their 
quality of life. 
To assess the cost of treatment for the patient. 
To establish the average cost of treatment for hypertension 
in the Mamre community. 
It is intended that the methodology achieved in this instance will be 
applicable to other similar studies. There may also be the possibility 
of using the data generated by the study for the formulation of health 
policy regarding antihypertensive drug use in a specific setting. 
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3. RESEARCH METHODS 
3.1. SETTING 
The study was conducted in Mamre, a village of approximately 5 000 
inhabitants, which was established as a Moravian Mission Station 
in 1808. It is situated 48kms up the west coast from Cape Town and 
5kms north of Atlantis. 
3.2. TEST POPULATION 
Mamre is a well established coloured community with strong 
traditions and it is considered representative of a community 
undergoing rural-urban transition. 
3.3. SAMPLE SIZE 
A statistician at the Institute of Biostatistics at the MRC was 
consulted in order to determine the sample size. A sample size of 
approximately 200 was deemed appropriate. 
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The following criteria determined the patient's inclusion in 
the study:-
(i) the patient must be resident in Mamre 
(ii) the patient must have been diagnosed by a doctor as 
having essential hypertension (i.e. the patient must 
have consistently exhibited a blood pressure above 
160/95 and if possible where other causes have been 
excluded.) 
(iii) the patient must have been on antihypertensive 
treatment for a minimum of three months and must 
currently be on that treatment. 
(iv) the patient must be 35 years or older. 
EXCLUSION CRITERIA 
The following criteria determined the patient's exclusion from 
the study:-
(i) pregnancy 
(ii) hypertension resulting from another cause 
(iii) treatment for less than three months or a change in 
treatment in the last three months. 
(iv) patients currently not on treatment 
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A list of patients, over 35 years, believed to be receiving 
treatment was drawn up from the following sources: 
(i) identified hypertensives from the baseline study 
(1986), the follow-up study of hypertensive women 
(1987) and the follow-up study of newly diagnosed 
hypertensives (1991) compiled by the Department of 
Community Health at the University of Cape Town. 
(ii) patients who attend the Mamre blood pressure station 
(iii) hypertensive patients who attend the Atlantis Day 
Hospital satellite clinic in Mamre 
(iv) hypertensives on treatment who are identified by the 
local clinic sisters, doctors and District Surgeons. 
A total of 247 hypertensive patients were listed and all 
were included in the study sample. 
3.5. DATA COLLECTION 
The required data was collected:-
(i) by means of an interviewer-administered questionnaire. 
(ii) from the patient's medical record or folder 
(iii) from the Register of Medical Practitioners (1991) compiled 
by the South African Medical and Dental Council. 
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THE QUESTIONNAIRE (appendix II) 
The questionnaire (appendix II) was drawn up according to 
the objectives of this study. It was translated into 
Afrikaans because this is the home language of the majority 
of Mamre residents. 
The questionnaire was divided up into 3 sections: 
(i) patient-related demographic data 
(ii) process data on drug use 
(iii) outcome data, which was further divided into 3 
sections:-
questions pertaining to social implications 
questions pertaining to economic implications 
questions pertaining to medical implications. 
Consideration was given to the sequence of the questions. 
Very personal questions, such as those relating to the 
participant's sex life, were positioned at the end of the 
questionnaire. Although the questionnaire was 8 pages long, 
it took on average 15 to 20 minutes to be filled out by the 
field worker. Two types of questions were used:-
(i) Closed-ended questions, where the respondent was asked 
to select an answer from a list provided, were predominantly 
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less variability between the two fieldworkers and could 
therefore be uniformly interpreted by the researcher. 
(ii) Open-ended questions or free response, where the 
respondents reply in their own words. This question form was 
used when it was not desirable to prompt or when further 
comments on a closed-end question were required. 
PATIENT DATA 
BACKGROUND DATA 
The data was collected by means of a interviewer-
administered questionnaire, in order to record the patient's 
place of residence, age, sex, highest level of education and 
any other diseases that he/ she may suffer from. The 
information on the other diseases was also checked against 
the doctors' records if these were available or with the 
records of the Mamre blood pressure clinic when no patient 
records were available from their regular doctor. 
Information on the level of education was recorded as this 
factor has been shown to influence the degree of compliance. 
Data on other diseases the patient suffers from is important 
in view of the fact that diseases such as diabetes and 
arthritis complicate the management of hypertension and 
affect patient compliance. 
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PROCESS DATA 
The questionnaire recorded where the patient receives 
treatment and the name of their doctor. These data were 
needed in order for the researcher to confirm the 
information supplied by the patient against the doctor's 
records and to establish the different prescribing patterns 
amongst the prescribers. 
The patient was asked what medicines they were taking, with 
the assistance of a tablet identification chart and how they 
were taking these medicines (i.e. dose, route, frequency of 
administration and duration of treatment). These data were 
checked, where possible, with the treatment written up by 
the doctor in the patient's records. The degree of 
concurrence between the patient-supplied data and the 
doctor's records was used to estimate the patient's 
compliance with treatment. One hundred percent concurrence 
was designated as compliant; poor or no concurrence was 
designated non-compliant and if the drug could not be 
indentified but how it was taken described and this found to 
be compatible with the doctors' notes then the patient was 
termed probably compliant. 
The use of other medicines, either prescribed or over-the-
counter, were also recorded in this part of the 
52 
3.5.2.3. 
Chapter 7. Research definition 
questionnaire in order to determine possible drug 
interactions. Two reputable reference books namely; 
Hansten's Drug Interactions (5th ed.) and Stockley's Drug 




The questionnaire was also used to establish the 
effect of treatment on the patients' daily life style 
(i.e. their quality of. life), their attitudes towards 
the medical service they use and how they feel on 
their treatment for high blood pressure. 
(ii) Economic: 
The questionnaire established the employment status of 
the sample population and who was responsible for the 
payment of medicines in this population. The cost of 
treatment to the patient was documented, if the 
patient paid for medicines. The cost of medicines paid 
for by medical aid schemes, was recorded as the retail 
price and was calculated using the retail pharmacy 
program Pharmassjst. Medicines supplied by the 
District Surgeons or the Government Hospitals were 
costed from the Cape Provincial Administration's 
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hospitals tender price list. The data will not be 
enough to establish cost-benefit ratios, as the study 
is not a longitudinal one. The questionnaire evaluated 
time taken off from work due to hypertension, or to 
consult a doctor and if the patients were financially 
penalised for absenteeism from the work place. 
(iii) Medical: 
The patient's blood pressure was documented from their 
medical records, if this information was available in 
the patient's records, in order to establish cost-
effectiveness of the antihypertensive drugs. Renal and 
liver function as well as the potassium, blood 
glucose, cholesterol and uric acid levels were also 
recorded from the patient's records. The biochemistry 
data were recorded in order to determine if any of the 
antihypertensive drugs were adversely affecting the 
patients biochemistry (eg. thiazide diuretics may 
adversely affect blood glucose, potassium levels, 
cholesterol and uric acid levels) (appendix III). 
The patient questionnaire ascertained, by means of 
spontaneous reporting (open-ended question), if the 
patient was experiencing any disturbing side effects 
and if these symptoms influenced compliance with their 
treatment. The patient was then prompted (close-ended 
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question) to report on a few of the more important and 
common side effects of antihypertensive drugs. This 
part of the questionnaire was adapted and translated 
from an already tried and validated, self-
administered quality of life questionnaire for 
hypertensive patients. (Bulpitt, C.J. et al; 1990) 
This questionnaire was found to be suitable for 
patients on diuretics, beta-blockers, calcium channel 
blockers, ACE inhibitors and centrally acting drugs. 
PRESCRIBER DATA (appendix IV) 
Data on the prescribers were obtained from the Register of 
Medical Practioners issued by the South African Medical and 
Dental Council and included the year of graduation, the 
university attended and any other additional qualifications 
(appendix III). 
3.6. SURVEY PROCEDURE 
This is a cross-sectional, descriptive study on the use and 
effects of antihypertensive drugs as they are being used in 
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Two interviewers visited the study population in their 
homes. Allocation of respondents was done on a geographical 
basis rather than by random selection, largely because this 
technique had been used by previous studies in Mamre. 
DEVELOPMENT PHASE 
The development phase was completed prior to the 
commencement of the study. This phase involved:-
(i) the development of a questionnaire, a prescriber data 
form and a form for recording information from the 
study participants' medical records, by the 
researcher. 
(ii) the development of explicit criteria by the 
researcher, in consultation with various specialists 
in the field and by reviewing the current literature. 
(iii) defining therapeutic goals for the treatment of 
essential hypertension in relation to age, sex and 
race. 
DATA COLLECTION 
Data collection was carried out by local fieldworkers, by 
means of interviews conducted in the respondents home. Data 
collection commenced on the 1st September 1991 and was 
completed by November 1991. Interviews usually took place 
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during the day but participants were visited at night if 
necessary. The researcher met weekly with the fieldworkers 
to check for correct completion of the questionnaires. 
Problems were addressed and if necessary the fieldworker 
would visit the respondent a second time to clarify their 
response. Fieldworkers were required to substantiate any 
missing data. The researcher then collected the data from 
the patients 1 records after all the respondents had 
completed the questionnaire. Data collection from the 
medical records was completed by April 1992. 
EVALUATION AND ANALYSIS PHASE 
The questionnaires were marked by the interviewers and then 
coded by the researcher, according to a set of coding rules 
drawn up prior to commencement of the analysis. Coding of 
the data was undertaken simultaneously with the fieldwork to 
allow for immediate correction of inconsistencies and 
completion of omissions. The coded data was then analysed at 
the Department of Biostatistics at the Medical Research 
Council in Parow, using the s~sR computer package. Variables 
were initially analysed using simple descriptive statistics. 
Detailed analysis of all possible data combinations was not 
attempted. Both parametric and non-parametric tests were 
used and a p value of less than 0.05 was regarded as 
statistically significant. The following tests were employed 
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depending on whether the data were of a continuous or 
discrete nature:-
(i) Pearson's Correlation Coefficients: 
a parametric test for correlation between 2 samples of 
data. 
(ii) Student's - t Test: 
a parametric test for significance between 2 
independent samples. 
(iii) Chi-square Test: 
a non-parametric test for association between 2 
variables. 
(iv) Analysis of Variance: 
an analysis of variation among more than 2 independent 
samples. 
FEEDBACK AND RE-EVALUATION OF CRITERIA 
The results will be reported to the Mamre Hypertension Group 
to assist in providing direction for their intervention 
program which will also involve a report back of the results 
to the participating doctors and then possible re-evaluation 
of the criteria. 
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REASSESSMENT 
This phase was not done as part of this study, but will be 
done as a separate study at the completion of the 
intervention phase currently being undertaken by the 
Department of Community Health (UCT), in Mamre. 
3.7. CHOICE OF INTERVIEWERS 
In setting up the Mamre Community Health Project the 
Department of Community Health (UCT) together with the Mamre 
Steering Committee decided that all the fieldworkers used in 
the studies should be selected from the Mamre community, as 
they would have the interest of the village at heart and 
would therefore be highly motivated. 
The following criteria were decided upon for the selection 
of fieldworkers:-
that they should be unemployed 
that they should be of the same sex 
that they should have at least a standard 8 education 
that they should be approximately 40 years old, as it 
was considered that this was necessary for questions 
referring to sexual function. 
Two fieldworkers were selected by the Sister-in-charge of 
the Mamre blood pressure monitoring station. 
60 
Chapter 7. Research definition 
3.8. TRAINING OF THE FIELDWORKERS 
Variability in interviewer technique has been shown to have 
a great effect on the repeatability of responses, therefore 
both fieldworkers received training from the MRC. This was a 
one-day training programme which included the following:-
background information and understanding of why the 
study was being conducted 
interviewing techniques 
confidentiality of information 
understanding and familiarity with the questionnaire 
recording of data 
a role-playing of the interview situation 
strategies for dealing with refusals 
The researcher participated in this training programme and 
supervised the data collection. 
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3.9. PILOT STUDY 
3.10. 
A pilot study was undertaken in Mamre as part of the 
fieldworkers' training program. It also served to test the 
appropriateness of the questionnaire (i.e. to assess whether 
it was answerable and the translation to Afrikaans was 
acceptable and understandable.) A few minor changes were 
made to the questionnaire at the end of this period in order 
to assist the fieldworkers in the recording of the data and 
to improve the clarity of some questions. Both the MRC 
fieldworker trainer and the researcher were satisfied that 
the interviewers understood the questionnaire and were 
consistent with each other. 
ETHICAL CONSIDERATIONS 
This study was approved by the Faculty of Medicine's Ethics 
Committee at the University of Cape Town prior to 
commencement of the study. 
Patients were informed of the details of the study by the 
fieldworkers and if they freely consented to participate, 
they were asked to sign their questionnaires. 
Confidentiality has been ensured by allocating each patient 
a study number. Confidentiality of the prescribing doctors 
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was similarly ensured and at no point in the report is any 
doctor mentioned by name. Permission to access the 
patient's medical records was obtained from both the patient 
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BACKGROUND DEMOGRAPHIC DATA 
A total of 247 patients were initially included in the study 
group. Of these, 41 were found to be no longer on treatment, 5 had 
left Mamre or could not be traced and 3 had died. Three people 




The selected study sample consisted of 144 (73.8%) females and 51 
(26.2%) males. 
1. 2. AGE 
Figure 8.1.2. 
The average age of the study population in years was 58.7, with a 
range of 36 to 85 years. The average age for the women was 59.6 
with a range of 36 to 85 years. The median age for the men was 
57.8 years, with a range of 37 to 80 years. The mode for both 
sexes was 60 years. 
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Females Males 
Average age (yrs) 59.6 57.8 
Range (yrs) 36-85 37-80 
TABLE 8.1.2 
The average age and age range (in years) of the study population. 
1.3. LEVEL OF EDUCATION 
Figure 8.1.3. 
The average level of education was to standard 5 or standard 6, 
with 67.7% of the study population having attained this level. 
Only 11.3% of the participants had a standard 8, 9 or 10 and a 
further 4.6% had received a tertiary education or trained in a 
technical skill. 
1.4. CHRONIC MEDICAL CONDITIONS 
Figure 8.1.4. 
The most common chronic medical conditions (apart from 
hypertension) in the study population were 11 gout 11 or rheumatic 
diseases, diabetes and heart disease. Nineteen percent of the 
participants reported that they suffered from 11 gout 11 , 15.9% from 
diabetes and 13.3% from heart problems. 
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2. USE OF MEDICAL SERVICES 
2.1. MEDICAL FACILITY AT WHICH TREATMENT FOR HYPERTENSION WAS 
RECEIVED. 
Figure 8.2.1. 
Analysis revealed that 66.7% (97 females and 33 males) of the study 
population attend a state facility while the remainder consult with 
private general practioners. 23.6% (6 males and 40 females) attend more 
than one medical facility. None of the respondents reported that they 
consulted alternative healers. 
2.2 PRESCRIBER CHARACTERISTICS 
Table 8.2.2. 
Fifteen different private doctors, in Mamre, Atlantis and Cape Town were 
consulted by 65 respondents. Two district surgeons (D.S) treated 76 of 
the respondents and 2 doctors at the Wesfleur day hospital treated 53 
respondents, many of whom were also seen by the district nurse at the 
Mamre district clinic. Nineteen patients were seen by doctors at 
Woodstock, Somerset and Groote Schuur hospitals. 
All but one of the doctors were male and the average number of years in 
practice for this group was 13 years, with a range of 4 - 37 years. All 
doctors practising in the Mamre/Atlantis area were fluent in Afrikaans. 
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State * Private 
University attended 
Stellenbosch 3 7 
Univ. Cape Town 1 4 
Orange Free State 0 1 
Pretoria 0 1 
Outside RSA 0 1 
Av. practice years 16.5 12.5 
Range (years) 4 - 37 5 - 25 
Additional qualifications 0 4 
TABLE 8.2.2. Characteristics of the state versus the private sector 
prescribers. 
(* excluding Groote Schuur, Woodstock and Somerset hospitals due to 
incomplete data) 
Figure 8.2.2 
Approximately two thirds (67.7%) of the study population did not see the 
same doctor each time they sought treatment for their hypertension. A 
comparison between the sexes showed that 56.9% of the men as opposed to 
71.5% of the women did not see the same doctor at each visit. 
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3. USE OF MEDICINES 
3.1. DRUGS USED TO TREAT HYPERTENSION 
Figures 8.3.1.1. and 8.3.1.2. 
Twenty seven different drugs, which could be grouped into 11 
pharmacological classes according to the ATC classification 
(appendix I), were used to treat the study population. 
ATC classification Generic name Freq % 
Centrally acting methyl dopa 68 25.9 
reserpine 20 7.6 
reserpine co. * 10 3.8 
rauwolfia co. 18 6.8 
Alpha-blockers prazosin 6 2.3 
Vasodilators hydrallazine 3 1.1 
Calcium antagonists nifedipine 1 0.4 
verapamil 5 1. 9 
diltiazem 1 0.4 
ACE inhibitors captopril 10 3.8 
enalapril 9 3.4 
lisinopril 1 0.4 
ramipril 1 0.4 
Thiazide diuretics hydrochlothiazide 2 0.8 
cyclopenthiazide 16 6.1 
Non-thiazide diuretic indapamide 16 6.1 
Loop diuretic furosemide 2 0.8 
K+ sparring diuretic spironolactone 2 0.8 
triamterene co. 12 4.6 
amiloride co. 43 16.3 
B-blockers;non-selective propranolol 3 1.1 
B-blockers;selective atenolol 12 4.6 
metoprolol 2 0.8 
TOTAL 263 100.0# 
(* reserpine co= BrinerdinR) (# rounded to 100.0%) 
TABLE 8.3.1. Drugs used to treat hypertension in the study population. 
70 
Chapter 8. Results 
It was noted that 61.5% (120) of the study population took only 
one drug for their hypertension, while 33.3% (65) and 5.1% (10) 
people took 2 and 3 drugs respectively. The drugs most commonly 
taken together where methyldopa, a reserpine containing agent or a 
diuretic. Prazosin was the most favoured third line agent. 
3.2. DRUG PRESCRIBED VERSUS THE MEDICAL FACILITY 
Figure 8.3.2. 
ATC classification Generic name Private D.Surg. Hosp. 
Centrally acting methyl dopa 13 31 
reserpine 11 9 
reserpine co. * 1 5 
rauwolfia co. 4 7 
Alpha-blockers prazosin - 1 
Vasodilators hydrallazine 1 1 
Calcium antagonists nifedipine 1 -
verapamil - 2 
diltiazem 1 -
ACE inhibitors captopril 7 3 
enalapril 7 1 
lisinopril 1 -
ramipril 1 -
Thiazide diuretics hydrochlothiaz. 1 1 
cyclopenthiazide 15 1 
Non-thiazide diuretic indapamide 4 11 
Loop diuretic furosemide - -
K+ sparring diuretic spironolactone 1 1 
triamterene co. 3 2 
amiloride co. 8 16 
B-blockers;non-select. propranolol 2 1 
B-blockers;selective atenolol 6 4 
metoprolol 1 -
TOTAL 89 97 
TABLE 8.3.2. Comparison of antihypertensive drugs prescribed by the 
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3.3. OTHER DRUGS TAKEN 
Table 8.3.3. 
A total of 60 different drugs, other than antihypertensives, were 
taken by 42.6% (83) of the study population. Twenty-nine (15%) 
people took one drug, 38 (19.5%) people took 2 drugs, 13 (6.7%) 
took 3 drugs and 3 (1.5%) people took 4 different other drugs. 
The following 10 drugs were the most commonly prescribed. The 
other 50 drugs were only prescribed once. 
Drug name Freq. of use 
Indomethacin 20 
Glibenclamide 17 
Drug unknown 11 
Metformin 9 
Isosorbide dinit subl. 7 






TABLE 8.3.3. The most commonly used other drugs. 
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SOCIAL CONSEQUENCES 
Social consequences were estimated according to the respondents' 
rating of their perception of the quality of the medical service 
they received, their perceived health on antihypertensive 
treatment, by estimating the patients' compliance with their 
treatment and evaluating their perceived quality of life. 
4.1. ATTITUDE TOWARDS THE MEDICAL SERVICE RECEIVED. 
Figure 8.4.1. 
When asked how they rate the medical service they receive, 88.2% 
of the participants rated it to be either excellent or good and 
only 3.1% considered the service to be poor or useless. 
4.2. PATIENTS PERCEPTION OF THEIR HEALTH ON ANTI-
HYPERTENSIVE TREATMENT. 
One hundred and sixty-six (85%) of the study population claimed 
that they felt better since starting their treatment for 
hypertension, while 29 (15%) said they felt no difference. None of 
the respondents claimed that the treatment made them feel worse. 
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4.3. ESTIMATED COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS 
Figure 8.4.3. 
The participants in the study were considered to be compliant with their 
drug treatment 62.1% of the time and probably compliant 9.0% of the 
time. Noncompliance for the group was estimated to be 15.8% and probable 
non compliance 13.1%. Due to records for some patients being 
unavailable, 72 (27.4%) of the antihypertensive drugs used could not be 
evaluated. 
4.4. QUALITY OF LIFE 
Figure 8.4.4. 
Normal daily activities were still being performed by 84% (n=163) of the 
study participants, 7% (n=14) could perform their daily tasks with 
effort, 4% (n=8) with assistance and 5% (n=lO) were incapacitated. 
Participants not able to continue with their normal daily activities 
complained of tiredness, general malaise, "gout" and 6 participants were 
debilitated as a result of heart attacks. 
The question on whether antihypertensive drugs or hypertension 
interferes with the study participants' leisure time was not analysed 
due to poor understanding of the question by the participants, which 
resulted in interviewer prompting. 
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5. ECONOMIC CONSEQUENCES 
5.1. EMPLOYMENT STATUS 
Figure 8.5.1. and Figure 8.5.1.2 
Only 24% (n=46) of the study population were in paid employment, 
38% (n=77) were pensioners, 7% (n=14) received a state medical 
grant, 28% (n=55) worked but were not paid for their work and just 
2% (n=3) were noted to be unemployed. Forty five percent (n=23) of 
the men and 16% (n=23) of the women were in paid employment, while 
37% (n=53) of the women and 4% (n=2) of the men were working but 
not being paid. 
5.2. RESPONSIBILITY FOR PAYMENT 
Figure 8.5.2. 
The state pays or subsidises 36% (n=69) of the participants 1 
medical treatment for hypertension, the medical schemes 21% (n= 
40), the employer 2% (n=4) and 40% (n=78) of the study 
participants were responsible for paying for their own treatment. 
Of those participants who were on medical aid, 39 (97.5%) 
consulted a private doctor. 
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5.3. AFFORDABILITY OF THE MEDICINES 
Figure 8.5.2. 
Of the 78 respondents who had to pay for their medical treatment 
themselves, 32 (41%) said they could afford it, while 41 (53%) 
could not. Five (6%) of the respondents claimed that they could 
sometimes afford their medical treatment. 
Patients who had to pay for their own consultations and medicines, 
whether they could afford it or not, paid significantly more than 
those for whom the medical aids paid or the state paid (p= 
<0.001). While the respondents 1 ability or inability to pay for 
their antihypertensive drugs did not significantly influence how 
much they paid each month for their medicines (p= 0.100). 
5.4. COST OF A DOCTORS VISIT 
Table 8.5.4. 
The cost, to the patient, for a visit to the doctor ranged from no 
cost (R0.00) to R95.00. The mean cost for the study population was 
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There was a statistically significant association (p= < 0.001) 
between how much patients paid to see a doctor (in rands) and the 
nature of the medical facility where the people sought medical 
care. If the patient paid for their own medicines then on average 
the most was paid by those who went to a day or teaching hospital, 
then a private doctor and the least was paid by patients who 
attended the district surgeon. 
District surgeon Private doctor Hospital Dr. 
R0.00 - 30.00 R o.oo - 95.00 R0.00 - 21. 00 
Rl.04 R 9.14 R5.80 
R0.00 R 0.00 R5.00 
R0.00 R 0.00 R5.00 
Std. dev 4.40 17.40 3.24 
TABLE 8.5.4. Doctor's fee according to the medical facility. 
5.5. COST OF ANTIHYPERTENSIVE DRUGS 
Table 8.5.5. 
The cost of antihypertensive drugs to the payer ranged from a 
negligable amount (ie. less than Rl.00) to R394.00. The mean cost 
was R25.91 (standard deviation 48.95), while the median was R8.00 
and the mode was R5.00. 
Who accepts payment for medical treatment also significantly 
influences the amount of money paid for medicines each month (p= < 
0.001). Medical aids pay the most for medicines, then patients who 
pay for their own medicines and the state pays the least. 
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District surgeon Private doctor Hospital Dr. 
Range R0.00 - 11. 00 R 0.00 - 394.00 R 0.00 - 45.00 
Mean R4.50 R62.89 Rl0.90 
Median R4.00 R41.00 R 8.00 
Mode R5.00 Rl0.00 R 8.00 
Std. dev. 2.91 69.92 10.76 
TABLE 8.5.5. The cost of hypertension treatment in relation to the 
medical facility used. 
5.6 ABSENTEEISM FROM WORK 
Tables 8.5.6.1. and 8.5.6.2. 
Of the 46 participants in full time paid employment, 91.3% (n=42) 
had not been absent from work during the last month due to their 
hypertension, 1 women and 1 man were absent for 2 days and 2 women 
had been absent for 3 working days in the last month. Participants 
took between O and 8 hours off work each month to consult a doctor 
for hypertension management. The mean time taken off work was 2,5 
hours, but the mode was O hours. All participants received their 
full salary despite absenteeism from work. 
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Days off Females Males Total % 
0 days 20 22 42 91. 3 
1 day 0 0 0 0.0 
2 days 1 1 2 4.3 
3 days 2 0 2 4. 3 
TOTAL 23 23 46 100.0# 











Days off work due to hypertension 
Females Males Total % 
14 12 26 56.4 
1 0 1 2.2 
1 0 1 2.2 
1 7 8 17.4 
1 0 1 2.2 
5 4 9 19.6 
23 23 46 100.00 
Hours off work to consult a doctor for hypertension 
management 
79 
Chapter 8. Results 
6. MEDICAL CONSEQUENCES 
6.1. APPROPRIATE USE OF ANTIHYPERTENSIVE DRUGS. 
Figure 8.6.1. 
A total of 267 scripts for antihypertensive drugs were issued. Use 
of these drugs was found to be correct 187 (70%) times, when 
judged against predetermined criteria (appendix V). Eleven (4%) of 
the drugs were excluded from evaluation due to inaccurate 
information from the respondent. Incorrect use was divided into 
the following sub-groups:-
(i) not appropriate for the management of hypertension (6% n = 
4) 
(ii) dose too high (71%; n = 49) 
(iii) combination product used (23% n = 16). 
6.2. SIDE EFFECTS OF ANTIHYPERTENSIVE TREATMENT 
(i) OCCURRENCE OF SIDE EFFECTS 
Figure 8.6.2.1. 
Spontaneous reporting of side effects was higher for the women 
than for the men; 50% (n=69) of the women as opposed to 23.5% 
(n=12) of the men volunteered that they experienced side effects, 
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Of the total study population, 41.5% (n=81), reported experiencing 
side effects with the antihypertensive drugs. 
SIDE EFFECTS EXPERIENCED 
Figure 8.6.2.2. 
The most commonly experienced side effect was that of tiredness 
(49%). Thirty one percent of those interviewed claimed to 
experience side effects only if they forgot to take their pills. 
Of the 81 people who experienced side effects, 5 decided to stop 
taking the drug, 8 made a modification to the prescribed treatment 
regimen and took their tablets only now and again, while the 
remaining 68 respondents continued to take their tablets as 
prescribed. 
SPECIFIC SIDE EFFECTS EXPERIENCED ON QUESTIONING 
Figure 8.6.2.3. 
When questioned about specific side effects which have been 
associated with the use of antihypertensive drugs, it was noted 
that the most commonly occurring effects where those of blurred 
vision (48%), leg cramps (43%), headache (39%) and the diuretic 
effect (34%). 
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Side effect Freq. % 
Blurred vision 94 48 
Leg cramps 83 43 
Headache 76 39 
Diuretic effect 67 34 
Hot flushes 65 33 
Sleepy 64 33 
Lightheaded 62 32 
Dry mouth 53 27 
Constipated 49 25 
Dry cough 39 20 
Cold fingers 31 16 
Bad dreams 29 15 
Blocked nose 26 13 
TABLE 8.6.2.3 Occurrence of specific side effects 
The question relating to the impact of the drugs on sexual 
function was not answered by 17 study participants and 140 
participants reported that they were no longer sexually active. Of 
the remaining 38 participants (20 females and 18 males) 21 
reported they had less interest in sex. The male respondents were 
asked about specific side effects relating to sexual function. Of 
the 51 male respondents, 18 were still sexually active and 10 of 
these men stated that they had problems in sustaining an erection 
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SIDE EFFECTS IN RELATION TO ANTIHYPERTENSIVE DRUGS 
Due to the relatively small sample sizes for the different types 
of antihypertensive drugs, only the following drugs were analysed, 
using the chi-squared test, against specific side effects :-
methyldopa (n=68), 
potassium sparing diuretics (n=57), 
reserpine containing drugs (n=48) and 
ACE inhibitors (n=21). 
The only statistically significant association was between ACE 
inhibitors and the effect of blurred vision (x2 = 0.005). 
6.3. BLOOD PRESSURE CONTROL 
6.3.1. 
The blood pressure of 43 participants could not be recorded as no 
medical records for these patients were available. 
SYSTOLIC BLOOD PRESSURE 
Figure 8.6.3.1. 
73% of the study participants were noted to have recorded blood 
pressures of less than 160mmHg, 7.5% had a reading of 160-169mmHg 
and 19.5% had systolic blood pressures of greater than 170mmHg. 
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6.3.2. DIASTOLIC BLOOD PRESSURE 
Figure 8.6.3.2. 
A diastolic blood pressure of less than 95mmHg was recorded for 
66.3% of the participants, a level of 95-99mmHg for 4.6% and 29.1% 
were noted to have a diastolic pressure greater than lOOmmHg. 
6.3.3 BLOOD PRESSURE CONTROL IN RELATION TO THE ANTIHYPERTENSIVE DRUG USED 
Table 8.6.3. 
Blood pressure control (less than or equal to 160/95mmHg) was 
statistically significantly related to the use of methyldopa and 











CONTROL NO. OF READINGS 









16 so 18 0.031 
20 43 12 0.738 
8 15 1 0.462 
5 15 3 0.365 
10 14 6 -0.032 
3 9 1 0.492 
14 19 2 -0.006 
4 8 4 0.742 
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BLOOD PRESSURE CONTROL IN RELATION TO THE MEDICAL FACILITY 
ATTENDED 
Table 8.6.3.4 
A blood pressure of greater than or equal to 160/95 was classified 
as not controlled. Nearly fifty percent (45.6%) of the 
participants blood pressure was controlled. Participants attending 
the state hospitals had the highest incidence of control (57.4%), 
while those that attended a private doctor were least controlled 
(33.8%). 
Dist.surgeon Hospital Private Total 
Freq ( % ) Freq ( % ) Freq ( % ) Freq ( % ) 
36 (47.4) 31 (57.4) 22 (33.8) 89 (45.6) 
24 (31.6) 15 (27.8) 24 ( 36. 9) 63 ( 32. 3) 
not recorded 16 (21.0) 8 ( 14. 8) 19 (29.2) 43 ( 22. 1) 
TOTAL 76 (100.0) 54 (100.0) 65#(100.0) 195 (100.0) 
(# rounded to 100.0%) 
TABLE 8.6.3.4 Blood pressure control according to the medical facility 
attended by the participant. 
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6.4. DRUG INTERACTIONS 
Table 8.6.4. 
Eighty eight (45.1%) of the study participants used one drug. In 
the remaining 107 participants, there was a theoretical risk of 39 
possible interactions occurring, where more than one drug was 
taken for hypertension or drugs were taken for other conditions. 
This incidence gives a probability that 1 patient in every 2 - 3 
is at risk of experiencing a drug interaction, if more than one 
drug is taken. The possible interactions were divided into the 
following sub-groups :-
Type of interaction Frequency ( % ) 
Major interactions 0 ( 0 . 0 ) 
Moderate interactions 11 (28.2) 
Minor interactions 17 ( 43. 6) 
Side effects exacerbated 11 ( 28. 2) 
Total 39(100.00) 
TABLE 8.6.4. Interactions between all the drugs. 
(appenddix I (5)) 
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BIOCHEMISTRY RESULTS 
( i ) Renal function 
Renal function Female Male Total 
Normal 2 1 3 
Mild renal failure 0 1 1 
Moderate renal failure 1 1 2 
Not recorded 141 48 189 
TABLE 8.6.5.1 Renal function recorded from the respondents' medical 
records. 
(ii) Liver function 
Liver function Female Male Total 
Normal enzymes 0 1 1 
Raised enzymes 1 1 2 
Not recorded 143 49 192 
TABLE 8.6.5.2. Liver functions recorded from the respondents medical 
records. 
(iii)Potassium level 
Potassium level Female Male Total 
Normal 2 2 4 
High 0 0 0 
Low 2 0 2 
Not recorded 140 49 189 
TABLE 8.6.5.3. Potassium levels recorded from the respondents medical 
records. 
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(iv) Total Cholesterol 
Total Cholesterol Female Male Total 
Normal range 7 2 9 
High 1 0 1 
Low 1 1 2 
Not recorded 135 48 183 
TABLE 8.6.5.4. Total cholesterol levels recorded from the respondents 
medical records. 
(v) Blood glucose 
Blood glucose Female Male Total 
Normal range 35 15 50 
Raised 31 7 38 
Not recorded 78 29 107 
TABLE 8.6.5.5. Blood glucose levels recorded from the respondents 
medical records. 
(vi) Uric acid levels 
Uric acid Female Male Total 
Normal 0 0 0 
Raised 1 1 2 
Not recorded 143 50 193 
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1. INTRODUCTION 
The purpose of this study was to develop a method to evaluate drug-use 
patterns in a South African community setting. Such methods have traditionally 
only been developed for hospital settings (Wible et al, 1988). 
While the randomised clinical trial (RCT) study design is the best method of 
assessing the efficacy of a given intervention, it has certain limitations. A 
small, select study population is used and selection criteria can result in 
biases. Drug utilisation methodologies include a wider spectrum of patients -
those with multiple pathological conditions, those on other medications as 
well as a wider age range and both sexes are described. Drug utilisation 
reviews describe how a drug or groups of drugs are being used in a 
11 real 11 
situation and what the consequences of their use are. 
The major aim of this work was not to describe the study population with 
regard to age, sex and education level and the outcomes of the use of 
antihypertensive drugs, but rather to produce a picture of the management of 
hypertension and the medical and socioeconomic consequences of 
antihypertensive drug use, for this population. The data reported in this 
study are applicable only to the Mamre community, but the methodology is 
applicable to other communities or areas. 
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2. LIMITATIONS OF THE STUDY 
The following study limitations need to be balanced against the results 
presented:-
(i) Interviewer bias. 
The two interviewers employed had different personalities, 
interviewer 1 was quiet and reserved while interviewer 2 was 
outgoing and communicative. These personality differences 
resulted in different approaches to the questionnaire and 
different interpretations of the responses, with the result that 
certain data were excluded from the analysis. Attention will be 
drawn to the actual differences noted between the two interviewers 
throughout the discussion of the results. 
(ii) Incomplete records. 
Medical records were not available for those participants who 
attended the district surgeons and records for other participants 
were often incomplete or inconsistent. This was further 
complicated by the fact that 46 of the participants attended more 
than one medical facility. Where possible, data for participants 
for whom no records were available were recorded from the Mamre 
blood pressure monitoring station. 
(iii)Observer bias. 
The participants blood pressure was recorded from their medical 
record and was not measured by the interviewer. The variability of 
instruments used and the number of observers could result in a 
bias. Blood pressure measurements recorded from the Mamre blood 
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pressure monitoring station were noted to show a zero end digit 
preference. 
(iv) Limited sample size. 
Due to the limited sample size, this study could not pick up 
accurate incidences of side effects due to a specific 
antihypertensive drug, but rather showed possible trends for side 
effects and evaluated whether the impact of any side effects 
experienced by the participants influenced compliance with their 
antihypertensive medicines. Owing to the fact that most of the 
participants took only one drug, the study population was not 
ideal for studying drug compliance. 
(v) Limited sample size. 
As a result of the small sample size sub-analysis of data was 
often not possible and statistically significant results unless 
otherwise indicated have been attributed to chance. 
(vi) Effectiveness of the antihypertensive drugs did not take into 
account the duration of treatment, the dose used, concomitant use 
of other drugs or the coexistence of other diseases (eg. 
diabetes). 
(vii) Despite the translated questionnaire being reviewed by members of 
the community for the correct colloquial Afrikaans translation and 
for ease of understanding the question, the questions relating to 
the participants• quality of life were not clearly understood. 
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3. PATIENT CHARACTERISTICS 
3.1 AGE AND SEX DISTRIBUTION 
Patient selection may have in part accounted for the fact that nearly 
three quarters - 73.8% - of the study participants were females. Of the 
records available at the Mamre blood pressure monitoring station, for 
patients currently receiving treatment for hypertension, 65% are female. 
Furthermore, studies previously carried out in Mamre on hypertension had 
only focused on the female population. There does, however, appear to be 
a greater incidence of hypertension in the female population of Mamre. 
The actual sex distribution of the total Mamre population is 
approximately the same for both sexes (female 50.4%; male 49.6%). The 
male to female ratio remains about 1.0 for all ages until the age of 45, 
after which it drops to reflect the higher life expectancy of women 
(Katzenellenbogen et al, 1988). This picture was reflected in the study 
population where the mean age for the females was 59.6 as opposed to 
57.8 years for the males. The oldest female participant was 85 and the 
oldest male 80 years. 
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3.2. LEVEL OF EDUCATION 
The level of education attained by the study participants correlated well 
with the rest of the population for the same age range. A total of 32.3% 
of the study participants had attained at least standard 6, as opposed 
to 39.7% for the whole population. This lies near the figure for 
coloureds in the Cape Peninsula (40.9%) and is slightly higher than the 
national figure of 31% for coloureds (Katzenellenbogen et al; 1988). A 
difference between the two interviewers for their respondents was noted. 
Interviewer 1 found that 36.9% of women had a standard 6 level of 
education while interviewer 2 found only 25.3%. The same situation was 
found for the men; interviewer 1, 42.3% had a standard 6 level while 
interviewer 2 found 32%. Interviewer 1 recorded that 58.2% of all her 
respondents had a standard 6 level of education, while interviewer 2 
reported only 44.2%. This difference is probably explained to a small 
degree by the fact that interviewer 2 had a slightly older study 
population (not statistically significant) than interviewer 1. 
Katzenellenbogen et al report that the tendency of the younger people to 
have a higher level of education than the older people reflects the 
changing educational profile of the South African population in general, 
and of coloured people in particular. 
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3.3. CHRONIC MEDICAL CONDITIONS 
Apart from hypertension it was found that diabetes, rheumatic diseases 
and heart disease were the most frequently reported chronic illnesses. 
The 1988 baseline study in Mamre supports these findings (Hoffman et 
al,1988), with the one exception of a lower incidence of heart disease 
for men, as opposed to this study which found a higher incidence. The 
prevalence of tuberculosis in the community was reported to be 10,8/1 
000, but none of the study participants reported that they were 
suffering from tuberculosis. Inquiry into a past history of tuberculosis 
might have corrected this discrepancy. 
4. MEDICAL FACILITIES 
The study participants 1 choice of which medical facility they would 
attend was largely governed by economic factors, with two-thirds of the 
participants attending a state facility (district surgeons, day hospital 
or other state hospitals). On the whole the elderly, the indigent and 
those on medical disability grants tended to consult the district 
surgeons, those on medical aids used the private doctors, while those 
with a small income tended to use either the day hospital in Atlantis or 
one of the larger hospitals in Cape Town. More respondents interviewed 
by interviewer 2 appeared to go to either the day hospital or to the 
district surgeon, but this difference was not statistically significant. 
Statistical differences seen here were probably due to selection bias of 
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respondents. Whilst none of the study participants consulted with 
alternative healers, the nursing staff working in Mamre reported a high 
use of traditional medicines by the population. 
The difference between the higher number of men than women who see the 
same doctor at each visit, can probably be attributed to the fact that 
more men (33%) attend private doctors than the state facilities, as 
opposed to the women (25%). About sixty percent (61.5%) of participants 
who consult with private doctors see the same doctor at each visit. 
5. DRUG USE PATTERNS 
Twenty-seven different antihypertensive drugs were prescribed by the 
private doctors, as opposed to 20 different drugs by the doctors in 
state controlled facilities. The drugs used in the management of 
hypertension by those doctors working for state facilities are largely 
determined by what is available for their use on the state tender 
system, whereas the private doctors are not constrained in their choice 
of antihypertensive agents. 
The drug most commonly used in this study population, methyldopa, is 
recommended only as a second-line agent in the management guidelines for 
hypertension in Southern Africa (Heart Foundation, 1992). Methyldopa is 
currently not considered as a first-line agent due to its side effects 
(sedation, lethargy, headache, blurred vision and decreased libido) and 
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possibly less compliance due to twice or three times daily dosing 
(Jackson, 1988). It is also relatively more expensive than other 
centrally acting agents such as reserpine (methyldopa - 9 cents/tablet; 
reserpine - 1 cent/tablet in the public sector). 
Reserpine and other reserpine containing drugs constituted 20% of the 
use of antihypertensive drugs, making them the third most commonly 
prescribed drug for hypertension. 
The management guidelines for hypertension in Southern Africa consider 
low-dose diuretics to be the first choice. Thiazides on their own 
accounted for only 7% of antihypertensives, while the combinations of 
amiloride or triamterene plus hydrochlorothiazide accounted for 22% of 
the prescribed antihypertensive drugs in the study population. 
The ten most commonly taken "other" drugs correlated with the diseases of 
highest prevalence for the study population. Indomethacin and 
diclophenac were taken for rheumatic conditions; isosorbide dinitrate 
sublingual (5mg) and tembids (40mg) and digoxin for heart disease; 
metformin, glibenclamide and insulin for diabetes, and benzodiazepines 
for nervous conditions. 
Polypharmacy, with either the antihypertensive drugs or the other drugs, 
was not a problem in this study population. Only 38.5% of participants 
took more than one antihypertensive drug and 42.6% were on 
antihypertensives plus a drug for other medical conditions. No 
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participant was on more than 4 different drugs. Participants most likely 
to be taking more than one drug were those who also suffered from other 
chronic diseases. 
6. SOCIAL CONSEQUENCES 
The vast majority (88.2%) of the study participants reported that they 
considered the medical service they attended to be either good or 
excellent and a similar percentage (85%) reported that they felt better 
since starting on antihypertensive drug treatment. This last finding is 
contrary to expectations, in that hypertension itself is normally 
asymptomatic and it is in fact the drug treatment that causes the 
patient to feel unwell (Mc Corvry et al, 1989; Williams, 1987). Since 
the baseline study of the Mamre community in November 1986 (Hoffman et 
al, 1988), numerous studies have been conducted in this community each 
year with the consequence that the Mamre population could be regarded as 
an over-researched community. At the time of this study another large 
study involving almost the entire community was being undertaken, with 
great personal benefit to the participants. The probability that the 
study participants answered these two questions in a way they thought 
would please the investigators, cannot be underestimated. 
This study determined that approximately 60% of the participants were 
compliant with their antihypertensive medicines. Although the method 
used to estimate compliance was not one of the conventionally recognised 
117 
Chapter 9 Discussion of Results 
ones, these findings are in keeping with a previous study of female 
hypertensives in Mamre where a compliance rate of 72.2% was reported 
(Marshall et al, 1988). The female participants were found to be more 
compliant than the males (64% vs 57%). The high level of compliance in 
this community could in part be attributed to the establishment of the 
Mamre blood pressure monitoring station and its numerous educational 
campaigns with regard to life-style modification programmes. 
An attempt was made to evaluate the impact of hypertension and the use 
of antihypertensive drugs on the participants• quality of life by 
estimating any negative impacts on performance of normal daily 
activities and interference with leisure or pleasure time activities. 
Both participants and fieldworkers were able to understand and answer 
the question relating to impact on their daily activities, but both 
groups experienced problems in interpreting the second question relating 
to the impact on their leisure or pleasure activities. This concept of 
leisure or pleasure time was not understood by this community. The 
consequence of the problem was that prompting by one of the 
fieldworkers was noted. A large number (75%) of her participants where 
reported to partake in some leisure activity as opposed to 23% for the 
other fieldworker. More specifically the first field worker noted that 
sixty seven respondents walked for pleasure, while only 4 respondents 
for the other fieldworker were found to walk as a leisure activity. This 
observation only became apparent after a few weeks and both interviewers 
were cautioned not to prompt for answers from the participants. The 
example of walking had been given to the fieldworkers in their training 
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program, so other possible examples were given to assist the 
fieldworkers explain this question. Unfortunately the cautionary advise 
was not heeded and this question had to be excluded from analysis. In 
retrospect the validity of such a question in a population which has an 
employment figure of approximately 36% requires questioning. It might 
have been beneficial to enlist the support of a social anthropologist 
during the questionnaire design phase. 
7. ECONOMIC CONSEQUENCES 
The figure of 24% for participants in paid employment is less than that 
of 64.7%, reported in 1986, for the total population (ages 15 - 65 
years). This differences can be attributed to the fact that 35% of the 
study participants were 65 years or more as opposed to only 4.5% for the 
total population. The fact that such a small percentage of the study 
population was in paid employment detracts from the power of the data 
relating to time off from work due to hypertension and for the purpose 
of consulting a doctor for their blood pressure measurements. However, 
from the small sample available for analysis, hypertension does not 
appear to significantly adversely affect the participants• performance 
in the work place. Ninety one percent of those participants in paid 
employment were never absent from work as a consequence of their 
hypertension and just less than fifty percent (43.6%) took time off from 
work for a doctors appointment. 
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Despite only 24% of the study population being in paid employment, 40% 
of the participants were responsible for paying for their medical 
treatment and just under half (41%) of them reported little difficulty 
in paying. There was no cost to the participant if they consulted the 
district surgeons or if their medical aid or their employer paid. This 
accounted for 58% of the participants and was therefore responsible for 
the mode and median payment being RO.OD. Participants who attended 
Wesfleur Day Hospital (27.2%), usually paid R5.00. The remaining 14.8% 
of the participants paid anything up to R95.00 for a visit to their 
doctor and their medicines. 
The cost of antihypertensive treatment in the community was evaluated in 
terms of how much the payer (state, medical aid, employer or individual) 
paid for drugs. This cost ranged from R394.00 (in the private sector) 
for a month's supply of tablets to less than Rl.00 (in the state 
sector). The large difference in the mean costs between the private and 
state sectors (R64.27 vs. R7.12) is largely due to the fact that drugs 
are infinitely cheaper when purchased through the state tender system as 
opposed to a private pharmacy or dispensing doctor (appendix VII). 
Furthermore the state tender system tends to purchase the cheapest 
generic brand of a drug as opposed to the more expensive original 
product, and little use is made of combination products which are 
usually more expensive than the individual agents given separately. With 
regards to the private sector; medical aids paid more for the same drug 
as opposed to the patient who bought the drug directly from the doctor. 
Dispensing doctors in this area had a flat rate for a consultation, 
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which included the cost of drugs. Those participants who were 
responsible paying for their own treatment, mostly consulted with 
private doctors, the day hospital or one the hospital in Cape Town. At 
all of these facilities the cost of the drug treatment was included in 
the overall fee and on average did not exceed R50.00. The major cost of 
drug treatment for hypertension in the Mamre community is therefore 
carried by a third party payer, namely the state or the medical aids. 
8. MEDICAL CONSEQUENCES 
8.1 APPROPRIATE USE OF ANTIHYPERTENSIVES 
The use of antihypertensive drugs in the study population was judged to 
be appropriate 74% of the time, after correcting for inaccurate 
information from the participants. Of those judged to be incorrect, 71% 
were considered to be on too high a dose. The most common offenders were 
the thiazide diuretics and drugs containing thiazide diuretics 
(ModureticR, DyazideR). The currently recommended dose is 12.5mg daily, 
whereas doses 2 - 4 times this amount were being used (Briant, 1991). 
The dose of atenolol was probably also greater than what was required 
for hypertension. It has been shown that atenolol has a flat dose-
response curve after 50mg daily (Opie, 1991). Higher doses therefore do 
not significantly influence hypertension control but do influence the 
adverse metabolic side effect profile. The use of furosemide as a single 
agent for the treatment of hypertension was considered to be 
inappropriate, except in patients with renal impairment or diabetes. The 
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World Health Organisation (WHO) does not recommend the use of 
combination drugs and therefore all combination drugs were classified as 
"incorrect use". Combination drugs are not advised on the grounds that 
the individual agents are usually cheaper than the combined drug, dosage 
adjustments might result in too high or too low a dose of one of the 
components being administered and, in the event of an adverse effect to 
a particular drug it is difficult to discern which is the causative 
agent. In this study population, however, no combination drug was used 
incorrectly according to the predetermined criteria. 
8.2. SIDE EFFECTS OF ANTIHYPERTENSIVE TREATMENT 
The questionnaire was designed to spontaneously elicit side effects that 
the participants perceived to be related to their antihypertensive drugs 
and only then prompted the participants about side effects commonly 
associated with antihypertensive drugs. Due to the small total sample 
size, incidences of side effects in this population cannot be 
extrapolated to expected current incidences of side effects for specific 
drugs. Furthermore, the experience of a certain effect could not always 
be separated from other potential causes. 
Just over forty percent (41.5%) of the participants spontaneously 
reported that they experienced side effects due to their 
antihypertensive drugs. Double the number of women experienced side 
effects as opposed to the men (50% versus 23.5%). Of these participants 
6.2% stopped taking the drug because of the side effects, while 9.9% 
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made dose adjustments. The figure of 41.5% for spontaneous reporting of 
side effects is low and figures as high as 70% have been reported (Dukes 
et al, 1988). Evidence that participants were responding as they thought 
the researcher would want, was demonstrated by the fact that 31% of 
these participants claimed they had unpleasant experiences if their 
blood pressure tablets were not taken. Short of this assumption being 
correct, it can only be deduced that the question was not clearly 
understood. The most commonly experienced side effect attributed to the 
antihypertensive drugs was that of tiredness (49%). This finding is in 
keeping with the fact that just over half (52%) the participants were on 
either methyldopa or reserpine-containing preparations. This side effect 
is well described for the centrally acting antiadrenergic drugs 
(appendix V). 
When specifically prompted about side effects known to be associated 
with antihypertensive drugs, however, the most commonly occurring side 
effect was found to be that of blurred vision (48%), and tiredness (33%) 
appeared sixth in line on the list of incidences. Methyldopa and 
prazosin have been associated with blurred vision and thiazide diuretics 
with visual disturbances (Holderness et al, 1991; Dukes et al, 1988). 
The high incidence of blurred vision in this study population group 
cannot in total be attributed to the use of these agents. Although the 
fieldworkers were trained to exclude poor eye sight, it is possible that 
participants had never had their eyes tested and were unaware that they 
had poor eyesight. The finding that ACE inhibitors are statistically 
significantly associated with blurred vision, must be attributed to 
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chance, as these drugs have not previously been associated with this 
side effect. A subsequent study (Salmon J. 1993) noted an unusually high 
incidence of glaucoma in the female population of Mamre. 
Nearly 60% of the participants were on a drug containing a thiazide or 
thiazide-like diuretic and these drugs could be responsible for the 43%
 
incidence of leg cramps and that 34% of participants were troubled by 
frequent micturition. 
The incidences of constipation (25%) and hot flushes (33%) associated 
with calcium antagonists and a dry cough associated with ACE inhibitor
s 
(20%) are in excess of the percentage of participants on those agents 
(3% and 8% respectively). 
The expected incidence of dry mouth associated with methyldopa and 
prazosin is in the order of 0.5 - 3% (Dukes et al, 1988). The actual 
frequency reported was 53 (27%). Other commonly used drugs known to 
cause dry mouth are the tricyclic antidepressants and to a lesser exte
nt 
the antihistamines, but neither of these two classes of drugs were used
 
extensively in this study population. 
Cold extremities or exacerbation of Raynaud
1 s phenomenon have been 
associated with the use of beta-blockers. Seventeen participants (8.7%)
 
were taking beta-blockers and 31 (16%) complained of cold fingers. The 
reported incidence of this effect is 0.5 - 6% (Dukes et al, 1988). 
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Bad dreams or nightmares have reportedly been associated with beta-
blockers, methyldopa, prazosin and the rauwolfia alkaloid drugs. One 
hundred and thirty nine (71.3%) participants were taking at least one of 
these agents and the incidence reported was 15% which translates to 29 
participants. 
Methyldopa, prazosin, rauwolfia alkaloids and hydralazine have all been 
associated with nasal congestion, although this effect is most uncommon 
with hydralazine. Nasal congestion is most commonly associated with the 
rauwolfia alkaloids while the incidences with methyldopa and prazosin 
are about 0.5 - 3%. Forty eight (24.6%) participants were taking 
rauwolfia alkaloids, 68 (25.9%) were on methyldopa and 6 (2.3%) were on 
prazosin. Despite the large number of people taking agents which could 
cause a blocked nose the actual incidence reported (13%) is higher than 
would be anticipated. 
The antihypertensive agents are well documented to be associated with 
adverse effects on sexual function. The most commonly associated agents 
are thiazide diuretics, beta-blockers, prazosin, spironolactone, 
methyldopa and hydralazine. While 86.7% of the participants used at 
least one of these agents, only 38 (19.5%) of them were still sexually 
active. Eighteen (35%) of the male participants were still sexually 
active and of these just over half (55.6%) were troubled by sexual 
dysfunction. 
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8.3 BLOOD PRESSURE CONTROL 
When viewed in terms of the systolic blood pressure, the participants 
could be classified as well controlled because nearly three quarters 
(73%) had a systolic blood pressure of less than 160mmHg. As far as the 
diastolic blood pressure is concerned, less (66.3%) of the participants 
were controlled. When both the systolic and the diastolic blood pressure 
are considered together, the number of participants whose systolic blood 
pressure is greater than or equal to 160mmHg and/or whose diastolic 
blood pressure is greater than or equal to 95mmHg drops to just less 
than half (45.6%) of the participants. This finding is in keeping with 
the 11 rule of halves 11 (previously explained in Chapter 6) which states 
that half of those hypertensives who receive treatment will be 
adequately controlled. 
A sub-analysis according to the medical facility where treatment was 
sought, revealed that those treated at the various state hospitals were 
the best controlled (57.4%), while those attending the private doctors 
were the least controlled (33.8%). The state hospitals also had the 
highest number of participants' blood pressures recorded. None of the 76 
patients attending the District Surgeons had their blood pressures 
recorded, all but 16 (21.1%) of these patients had records at the Mamre 
blood pressure monitoring station. Nearly thirty percent (29.2%) of 
those participants consulting with private doctors did not have blood 
pressures recorded. This was more a problem of tracing the patient 
record as some patients continuously move between doctors or do not 
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consult their doctor regularly for their blood pressure. Blood pressure 
values not recorded wit~in the last 6 months were excluded. Where 
patient files could be traced in the private sector, the blood pressure 
and current treatment were nearly always recorded. Twenty two percent 
(n=43) of the total study population did not have their blood pressure 
recorded. 
A sub-analysis according to the drugs used to treat hypertension 
revealed that adequate blood pressure control was statistically 
significantly related to the use of methyldopa and that poor control was 
associated with the use of reserpine and ACE inhibitors. The poor 
control associated with the ACE inhibitors, could be attributed to the 
fact that this agent was predominantly prescribed in the private sector 
and the high cost of the drug could have resulted in non-compliance. On 
the other hand, 60% of those patients consulting a private doctor are on 
medical aids and therefore do not bear the cost of the drug. Most 
studies show ACE inhibitors to be very effective drugs with a good 
quality of life profile (Croog et al, 1986). The findings of this study 
could therefore be either attributed to statistical error due to the 
small sample size (n=21) or to the possibility that these agents are 
not as effective in fhis population. The latter possibility cannot be 
determined from this study as it is a purely descriptive study. A 
separate randomised control trial would be required to evaluate this 
possiblility. For the same reasons, it is also impossible to determine 
why methyldopa should be associated with adequate control and reserpine 
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with poor control when both drugs are of the same class (centrally 
acting agents) with a similar pharmacological spectrum of side effects. 
8.4 DRUG INTERACTIONS (Detailed in Appendix VI) 
Of the 107 participants who took more than one drug either for their 
hypertension or for another medical condition, 36.4% were at risk of a 
possible drug interaction. 
The possible interactions were classified according to severity. None 
were found to be of major clinical significance, 28.2% of moderate 
significance and 43.6% of minor clinical significance. 
Eleven (28.2%) of the interactions were classified as being due to an 
additive effect of individual drugs side effects because of being taken 
together. The most common possible side effects involved the use of the 
potassium-sparing/ thiazide diuretic combination products. Two of these 
agents were often used together resulting in cumulative adverse effects 
of the thiazide component. They were also used in combination with an 
ACE inhibitor which could possibly result in hyperkalaemia (n=8). There 
were seven cases of the thiazide and related diuretics being used 
together with the non-steroidal anti-inflammatory drugs which results in 
the efficacy of the thiazides being reduced. 
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8.5 BIOCHEMISTRY 
Six of the total study population had their renal function monitored and 
of these 3 where known to be receiving treatment for either mild or 
moderate renal failure. Only one patient had his liver enzymes checked 
even though the most widely used drug was methyldopa. All drugs 
containing thiazide diuretics and the beta-blockers are known to have an 
adverse effects on blood potassium levels, cholesterol, glucose and uric 
acid levels. Six of the participants had documented potassium levels, 12 
had their total cholesterol recorded and none had uric acid levels 
documented. The highest incidence of blood chemistry being documented 
was for blood glucose levels where 88 (44.8%) of the participants had a 
level recorded. Most of these readings were obtained from the Mamre 
blood pressure monitoring station where it is routine practice to do a 
finger-prick blood glucose level. 
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9. SUMMARY OF THE AVERAGE HYPERTENSIVE PATIENT 
IN THE STUDY 
POPULATION 
The average hypertensive patient in the study population was a 
59 - 60 
year old female, with a standard 5 or 6 education. 
She would have about a 33% probability of also suffering from jo
int 
pains, diabetes or heart problems and would be taking one drug 
for the 
relevant condition. 
She would consult with either one of the district surgeons or w
ith a 
doctor at Wesfleur Hospital in Atlantis and would be unlikely to
 see the 
same doctor at each follow-up visit. The doctor would prescribe 
one of 
the following drugs for her hypertension; methyldopa, amiloride 
co. or a 
reserpine/rauwolfia containing drug. 
The patient will be very satisfied with the medical care she is
 
receiving, perceive herself to feel much better when she takes 
her 
tablets correctly and will probably be compliant. 
She will most probably be in unpaid employment or a pensioner. 
The 
average cost of her medicines to the state for a one months sup
ply will 
be R7.12. She will pay on average R3.00 per visit to the doctor 
and most 
often will find herself financially burdened. 
She will have a 50% chance of experiencing side effects due to 
her 
antihypertensive drug, but is unlikely to stop taking her medic
ine. The 
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most likely side effects experienced will be blurred vision, leg cramps, 
headaches and urinary frequency due to the diuretic effect. She is 
unlikely to be at risk of experiencing a drug interaction, but if she is 
taking any other medicines the incidence of experiencing a drug 
interaction is 33-50%. The probability that her blood pressure is 
controlled is just less than 50%. 
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CHAPTER 10. CONCLUSION AND RECOMMENDATIONS 
CONCLUSION 
What can be concluded from this research has largely been covere
d in the 
discussion of the results and the conclusions reached are only 
applicable to the Mamre community. 
1. The participants
1 perception of their well being was not impaired 
by their use of antihypertensive drugs and the side effects of 
these agents did not appear to interfere with the normal everyda
y 
activities of the participants. 
2. The major burden for the cost of antihypertensive drug treatment 
was borne by the state and the medical aid companies and not by 
the study participants. However, of the 78 (40%) participants who 
had to pay for their own treatment, just over fifty percent could 
not afford it. 
3. More than twenty different doctors prescribed 27 differen
t 
antihypertensive drugs to the 195 study participants. The overa
ll 
use of these agents was largely considered to be appropriate and
 
blood pressure was controlled in about 50% of the participants, 
for whom medical records were available. The assumption was mad
e 
that the initial diagnosis of hypertension was correct. 
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4. While the cost of the drugs prescribed ranged from 1.1 cents to 
410.6 cents for an average daily dose depending on which medical 
facility the participant attended, blood pressure control did not 
improve with increasing drug cost. In fact, control decreased with 
increasing drug costs. 
RECOMMENDATIONS 
Arising from the findings of this study and the insight gained, the 
following recommendations are made: 
1. The assistance of a social anthropologist is essential in 
developing 11 quality of life 11 assessment tools for 
antihypertensive drugs, which will be applicable to the various 
South African ethnic groups. 
2. Similar research projects need to be undertaken in other parts of 
the country and amongst other population groups. The drug use 
patterns of antihypertensive drugs and the consequences of their 
use should be established and correlated for the whole South 
African population before a definitive guideline for the 
management and treatment of hypertension is compiled. 
3. Arising from the finding that ACE inhibitors were found to be 
associated with poor blood pressure control, further studies would 
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be helpful in determining the efficacy of ACE inhibitors in this 
sub-set of the population. 
4. Although the use of antihypertensive agents on the whole were 
found to be appropriate, the dose was evaluated as being too high 
in 49 instances. The doses used, however, did not exceed those 
recommended in the package inserts. Continuing education of all 
health professionals in the management of hypertension and in the 
new developments is therefore essential in order to prevent 
unnecessary or excessive drug treatment, which often does not 
improve the medical outcome and only contributes to greater side 
effects. Emphasis should also be placed on the importance of 
keeping accurate patient records. 
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APPENDIX I 
GLOSSARY OF TERMS 
1. BACKGROUND DATA 
Patient background data refers to the patients age, sex, education 
level, diseases that they might suffer from and how these diseases are 
being treated. Background data on the prescriber refers to the year of 
qualification, the university attended and any additional qualifications 
of the doctor. 
2. BASELINE DATA 
Baseline data refers to what drugs are being used in the treatment of 
hypertension, how the drugs are being used and who is prescribing the 
drugs. 
3. COST-BENEFIT ANALYSIS 
Cost-benefit analysis is more strictly confined to studies where both 
the resources used in an activity and the benefits which it can yield 
can be expressed in monetary terms and therefore forces an explicit 
decision on whether the cost is worth the benefit (Eisenberg John M, 
1989). 
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4. COST-EFFECTIVENESS ANALYSIS 
Cost-effectiveness analysis measures the net cost of providing a service 
as well as the outcomes obtained. No clinical service or treatment can 
be considered cost effective in isolation, it must be compared with at 
least one other service or treatment. Therefore cost effectiveness 
analysis compare the cost of achieving the same outcome by a variety of 
different methods 
(Eisenberg John M, 1989). 
5. DRUG INTERACTIONS 
An interaction is said to occur when the effects of one 
drug are changed by the presence of another drug, food, drink or by some 
environmental chemical agent. For the purpose of this study interactions 
have been classified into 4 sub-groups:-
(a) Major Clinical Significance -
An interaction which has the potential to harm the patient. 
{b) Moderate Clinical Significance -
(c) 
(d) 
An interaction where the potential to harm the patient is less. 
Minor Clinical Significance -
An interaction where the potential to harm the patient is slight 
or the incidence of the interaction is quite low. 
Exacerbation of Side Effects -
The concomitant use of drugs results in the side effects of one or 
both of the drugs being "additive" (Hansten PD. 1985). 
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6. DRUG UTILISATION REVIEW 
The World Health Organisation defines drug utilisation review as the 
marketing, distribution, prescription and the use of drugs in a society, 
with special emphasis on the resulting medical, social and economic 
consequences (Grimsson, 1980). 
7. EXPLICIT CRITERIA 
Explicit criteria are predetermined elements (by consensus) of health 
care against which aspects of the quality, medical necessity and the 
appropriateness of a health service may be compared. Explicit criteria 
are usually written and very specific as opposed to implicit criteria 
which are normally unstructured, unwritten and hence individually 
determined (Gregoire, 1987). 
8. PRIMARY HEALTH CARE 
Primary health care as defined by the World Health Organisation is 
essential health care based on practical, scientifically sound and 
socially acceptable methods and technology made universally accessible 
to individuals and families in the community through their full 
participation and at a cost that the community and the country can 
afford to maintain at every stage of their development in the spirit of 
self-reliance and self-determination.--------------------------.It is 
the first level of the contact of individuals, the family and the 
community with the national health system bringing health care as close 
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as possible to where people live and work, and constitutes the first 
element of a continuing health care process (Mathews et al, 1989). 
10. QUALITY OF LIFE 
Quality of life is normally assessed in terms of the ability of an 
individual to contribute fully to, and derive satisfaction from, the 
normal activities of life, including work, marriage, family life and 
leisure activities. It may also be assessed in terms of freedom from 
physical and psychiatric symptoms and from the impairment in physical 
and mental functioning (Seedat, 1991). 
11. ATC (Anatom;cal, Therapeut;c and Chem;cal) CLASSIFICATION INDEX 
This is a classification index devised by the Nordic council on 
Medicines and the WHO Collaborating Centre for Drug Statistics 
Methodology. It groups pharmaceutical agents according to their 




DRUG UTILISATION REVIEW : PATIENT QUESTIONNAIRE 
Name of field worker: 
Date of interview:~-/~_/~ 
SECTION A: BACKGROUND DATA 
(1) Patient name: 
(2) Project number: 
" (3) Place of residence: 









( 6 ) What level of schooling or post level schooling do you 
have? 
( 7 ) (a) 
( 1 ) 
( 2) 
Do you suffer from any diseases? 
yes 
no 
, ... I~ 
D,~ 
If you answered yes, what do you suffer from? 
(b) Do you suffer from any of the following diseases? 
(1) asthma 
(2) diabetes 
(3) renal disease 
(4) heart disease 
( 5) TB 





(8) Are you taking any pills for any of these diseases? 
(1) yes D 
( 2) no 
2 ... 
If no, ignore question 9 and proceed to section B. 
(9) If yes, what medicines are you taking? (medicines for 
hypertension must be recorded in section B, question 2. 
Drug Dose Route Freq Duration 
SECTION B: PROCESS DATA 
(1) Do you know if you have high blood pressure? 
(1) yes 








(2) What medicines are you taking for your blood pressure? 
(Tick in the column SEEN if you confirmed the data with 
by seeing the tablets and packets) 








( 3 ) 
( 5) 
( 4 ) 
Where do you go for treatment for your blood pressure? 
( 1) Day hospital (name. ________ ) 
(2) District surgeon (place ) 
(3) GP (place ) 
(4) PHC clinic (place ) 
Hospital clinic/ out patients 
(name _______ _ 




see a doctor, do you always see the same 
( 2) no 
Comment: __________________ _ a:: 
SECTION C: OUTCOME DATA 
I. SOCIAL CONSEQUENCES 
( 1 ) How do you rate the medical service that you receive? 
( 2 ) 
( 1 ) excellent 
( 2 ) good 
( 3) average 
( 4 ) poor 
( 5) completely 
Why? 
In general how 
(1) better 












( 4 ) 
( 5 ) 
During the last month have you been unable, due to your 
health, to carry out your usual activities around the 
house and garden? D 
(1) normal activities performed 
(2) activities carried out alone with effort ~ 
(3) activities carried out with assistance 
(4) completely disabled 
If the reply was number 1, proceed to question 5. 
What were the reasons that you were unable to carry out 
your normal activities? 
El 
Do you have any leisure and/ or pleasure activities? 
(1) yes D 
( 2) no ... 
If no, ignore questions 6 and 7 and proceed to the next 
section. 
(6) If yes, please list these activities. 
(7) Has your state of health interfered with these 
activities recently? D 
(1) normal activities possible 
(2) carried out alone but with effort ,~ 
(3) only achieved with assistance 
(4) unable to carry out any of these activities 
II. ECONOMIC CONSEQUENCES 
( 1 ) Tick 
( 1 ) 
( 2 ) 
( 3 ) 
( 4 ) 
the answer that best explains your situation? 
In paid employment (fulltime / part time) 
not in paid employment but working around 
the house or looking after relatives etc. D 
unemployed but looking for work 










( 4 ) 
( 5) 
pays for your medicines? 
no cost (eg. State pays) 
self 
employer 
medical aid/ benefit 
other (specify ________________ _ 
If you pay in full each month for your medicines, how 
much do you pay? 
R _____ _ 
(4) How much do you pay to see the doctor? 
R ------- I I ,., 'Le> 
Can you afford to pay for your medicines 
doctor? 
and to see the 
( 5 ) 
( 6 ) 
( 7 ) 
------------------
How many days did you take off work last month due to 
your high blood pressure? days 
Do you have to take time off work to see 





(1) yes (specify the hours taken off an average 
each week hours) 
( 2) no 
2.S 
Do you still receive your pay if you take off time to 
see your doctor? 
(1) yes (100% received) 
(2) >50% received 
(3) <50% received 
(4) no (0% received) 
D 
'2.~ 
III. MEDICAL CONSEQUENCES 
( 1) (a) Have you ever experienced any side effects 
unpleasant experiences since starting your 
pressure tablets? 
(1) yes (specify ------------









(l)(b) Do any of the unpleasant effects of your medicine 
prevent you from taking your tablets as 
prescribed? 
(1) yes D 
(2) nearly always 
(3) hardly ever ~~ 
( 4) no 
Comments=~-~-~-~--~-~~~-~----~ 
QUESTIONS 2 TO 16: IF THE RESPONDENTS ANSWERS YES, THEN 
PLEASE WRITE "STOPPED" NEXT TO THE ANSWER IF THE EFFECTS 
CAUSED THE TABLETS NOT TO BE TAKEN. 
( 2) In the last month have you suf fer_e_d_f_r_o_m_l_i-gh) t-a~-s 
headedness, faintness or dizziness? 
(1) yes (specify when it happens 
( 2) no lw 
(3) In the last month have you often felt unusually sleepy 
during the day? 
(1) yes D 
( 2) no 
·n 
(4) Have you in the last month noticed weakness in the 
limbs? 
(1) yes D 
( 2) no 
(5) Have you in the last month had blurring of vision? 
(1) yes D 
( 2) no 
(6) How many times, on average, do you rise at night to 
pass urine? 
( 1) 0 
l1 
l"I 
(2) 1 B"'o ( 3) 2 
(4) more than twice (specify) 
41 
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(7)(a) In the last month have you suffered from a dry 
mouth? 
(1) yes D 
( 2) no 
If no, proceed to question 8 
L.~ 
(7)(b) If yes, does the dry mouth interfere with talking 
or eating? 
(1) yes D 
( 2) no 
(8) In the last month have you ever been troubled by a 
blocked nose (other than when you have had a cold)? 
(1) yes D 
( 2) no 
4~ 
"'"' 
(9) In the last month have you ever felt flushing of the 
face or neck? 
(1) yes D 
(2) no . ~ 
(10) Within the last month has there been a change in what 
you dream about? 
(1) yes D 
( 2) no 
(ll)(a) Do your fingers go white in the cold weather? 
(1) yes D 
( 2) no 
If no, proceed to question 12 
(ll)(b) 
(12)(a} 
If yes, do they become painful? 
(1) yes 
( 2) no 
Have you, in the last month, suffered from 
headaches? 
(1) yes 
( 2) no 
If no, proceed to question 13 
(12)(b) If yes, how often do the headaches occur? 





(2) 1-6 times a week D 
(3) 1 or more times per day So 
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(13) In the last month have you suffered from a dry cough? 
(1) yes D 
( 2) no 
SI 
(14) Have you in the last month been unusually constipated? 
(1) yes D 
( 2) no 
S2. 
Questions 16 and 17 relate to your sex life. While we 
appreciate that this information is of a personal nature, we 
are interested in all aspects of your well being and would 
like you to answer them. 
(16)(a) 
( 1 ) 




Do you have sexual intercourse? 
yes 
no (specify if this is for any medical 
reason ------------------
Is your interest in sex-
(2) the same 
(1) less D 
(3) greater s~ 
than before you started taking your blood pressure 
tablets? 
FOR MEN ONLY 
During sexual intercourse are you troubled by 
failure to sustain an erection? 
(1) yes D 
( 2) no 
S'S" 
During intercourse are you troubled by failure to 
ejaculate? 
(1) yes D 
( 2) no 
~(., 
(1) Identified from baseline survey 
(2) Identified from Mamre BP clinic 
(3) Both 1 and 2 
(4) Identified by health workers in the area 
Mamre blood pressure number: 
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APPENDIX Ill 
DRUG UTILISATION REVIEW : DOCTORS' RECORDS 
(1) Patient name: 
( 2 ) Project number: 
I 
\ 
( 3 ) Name of doctor: 
"' 
(4) Chronic diseases recorded by the doctor: 
( 5) 
( 1 ) 
( 2 ) 
( 3 ) 
Blood pressure 
( 1 ) systolic 
( 2 ) diastolic 
(nearest to date of 
mmHg 
mmHg 











I I I 





(7) What medicines have been prescribed for the high blood 
pressure? 





(8) What other medicines have been prescribed? 








(9) Renal function: 
(10) Liver function: 
(1) normal 
(2) mild renal failure 
(3) moderate renal failure 
(4) severe renal failure 
(5) not recorded 
(1) normal 
(2) raised liver enzymes 
(3) not recorded 
(11) Potassium level: 
(1) normal range 
( 2) high 
( 3) low 
(4) not recorded 
(12) Cholesterol level: (a) HDL(b) LDL(c) Total 
D~, 
Cholesterol 
(1) normal range: 
(2) high 
(3) low 
(4) not recorded: 
(13) Blood glucose: 
(14) Uric acid: 
(1) normal 
(2) raised 
(3) not recorded 
(1) normal 
(2) raised 
(3) not recorded 
APPENDIX IV 
DRUG UTILISATION REVIEW: PRESCRIBER DATA 
(1) Doctors name: 
(2) Place of work: 
(1) private practice 
(2) district surgeon 
(3) day hospital 
(4) teaching hospital 
(3) University attended 
Town 
Country 
(4) Year of graduation: 
19 (years in practice:~~~ 








ANTIHYPERTENSIVE DRUG PROFILES. 
These profiles are not intended to be complete reference works. Unless 
otherwise indicated the greater part of these profiles have been compiled 
from the following reference sources :-
Therapeutic Drugs (Dollery et al, 1991) 
The South African Medicines Formulary (Holderness et al, 1991) 
The American Hospital Formulary Service (McEvoy et al, 1993) 
Martindale, The Extra Pharmacopeia (Reynolds et al, 1989) 
Drugs for the heart (Opie, 1991). 
These protocols, together with the manufacturer 1 s package insert of the drug, 
were used as the criteria for assessing the appropriate use of 
antihypertensive drugs in the study population. 
ANTIADRENERGICS, CENTRALLY ACTING 
RESERPINE 
MECHANISM OF ACTION : 
Reserpine acts by binding to and destroying the granular noradrenaline storage 
vesicles in central and peripheral adrenergic neurons, resulting in the nerve 
endings losing their ability to concentrate and store noradrenaline and 
dopamine (Goodman & Gilman, 1990). Catecholamines leak into the cytoplasm, 
where they are destroyed by intraneuronal monoamine oxidase, and little or no 
active transmitter is discharged from nerve endings when they are depolarised. 
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The depletion of noradrenaline rather than the CNS effect is thought to be 
responsible for the antihypertensive effect. Reserpine reduces both cardiac 
output and peripheral resistance. 
PHARMACOKINETICS : 
The elimination T1; 2 is in the order of 1 - 2 weeks and effects may persist 
for many days or weeks after the drug is stopped. 
ADVERSE EFFECTS: 
The adverse effects are usually dose related. The most common adverse effect 
are drowsiness, fatigue, dizziness, depression, decreased libido and nasal 
stuffiness 
DOSE : 
Reserpine's kinetics allow once daily dosage (0.05 - 0.1 mg) (Opie, 1991) and 
ensure that sporadic missed doses have little or no effect on blood pressure 
levels (Luxenberg & Feigenbaum, 1983). 
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METHYL DOPA 
MECHANISM OF ACTION : 
Methyldopa is metabolised to false transmitters in the brain and this central 
effect is thought to be responsible for its antihypertensive activity (Goodman 
& Gilman, 1990). It reduces sympathetic outflow from the CNS and a decrease in 
plasma renin activity. The long-term hypotensive effect is accompanied by a 
decrease in both cardiac output and peripheral resistance (Jackson, 1988). 
PHARMACOKINETICS : 
The plasma T1; 2 is 1 - 2 hours, with hypotensive activity lasting between 10 -
24 hours. The onset of action is slow and oral bioavailability is low because 
of poor absorption and extensive first-pass metabolism. 
ADVERSE EFFECTS : 
It commonly causes sedation, lethargy, forgetfulness and the inability to 
concentrate (Jackson, 1988). Other frequently occurring side effects are 
headache, dizziness, blurred vision, decreased libido and dry mouth. 
DOSE : 
A dose of up to 2 - 3g per day in two to three divided doses may be required 
for hypertension. 
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ANTIADRENERGICS, PERIPHERALLY ACTING 
PRAZOSIN /DOXAZOSIN 
MECHANISM OF ACTION : 
They block the post-synaptic alpha1-adrenergic receptors causing dilatation of 
both the peripheral arterial and venous systems. This leads to a fall in 




B:raze~ undergoes substantial first-pass metabolism and oral bioavailability 
varies widely (40 - 80%) (Goodman & Gilman, 1990). Onset of antihypertensive 
effect is within 2 hours, but weeks may be required for optimal efficacy. The 
plasma T1; 2 is 3 hours, and the duration of action of brazes is 4 - 6 hours. 
Brazes is metabolised in the liver are excreted in the bile and faeces. 
ADVERSE EFFECTS : 
Most commonly they cause dizziness, lack of energy, palpitations, weakness, 
drowsiness, headache)first dose orthostatic hypotension and nausea. These 
effects may be diminished with continuous therapy or may be relieved by a 
reduction in dosage. 
DOSE : 
The recommended starting dose is 0.5mg twice or three 3 times a day, 
increasing slowly to a daily dose not greater than 20mg. 
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AGENTS ACTING ON ARTERIOLAR SMOOTH MUSCLE 
HYDRAZINOPHTHALAZINE DERIVATIVES 
HYDRALAZINE 
MECHANISM OF ACTION 
It acts directly on arterial smooth muscle to cause vasodilation and a 
reduction in total peripheral vascular resistance. Hydralazine decreases the 
diastolic more than the systolic blood pressure by lowering peripheral 
resistance (McAreavey et al, 1984). It increases heart rate, stroke volume and 
cardiac output. 
PHARMACOKINETICS : 
The oral biovailability of hydralazine is low (30 -50%) due to first-pass 
metabolism and may vary according to acetylator status (Goodman & Gilman, 
1990). The plasma T112 is about 1 hour, but antihypertensive effects persists 
for considerably longer (12 hours) because the drug is taken up by the 
arterial wall. Hydralazine is acetylated in the liver then excreted via the 
kidney. 
ADVERSE EFFECTS : 
The most frequently occurring adverse effects are headache, palpitations, 
postural hypotension and tachycardia. After 2 months use or with doses 
exceeding 200mg daily or in slow acetylators a syndrome resembling systemic 
lupus erythematosus and rheumatoid like arthropathy may occur. 
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DOSE : 
The usual starting dose is 20 - 25 mg twice daily, increasing gradually to 25 
- 75 mg every 6 - 8 hours. 
CALCIUM ANTAGONISTS 
MECHANISM OF ACTION : 
As a class their dominant effect is a decrease in peripheral vascular 
resistance. They limit calcium ion entry via the voltage-sensitive (slow) 
calcium channel, thereby reducing availability of calcium from the 
sarcoplasmic reticulum and decreasing contractility of arterial muscle. The 




Oral bioavailability is small (20 - 30%) due to first-pass metabolism in the 
liver. The elimination T1/ 2 is 3 - 7 hours, but can be up to 12 hours with 
repeated doses. Several metabolites are formed in the liver, and approximately 
70% of the drug and its metabolites are excreted in the liver. Norverapamil is 
an active metabolite and may accumulate in renal impairment. 
ADVERSE EFFECTS : 
Verapamil frequently causes the transient elevation of liver enzymes. Other 
effects include constipation, nausea, headache, dizziness, fatigue and facial 
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flushing. Females may be troubled by ankle swelling not due to fluid 
retention. 
DOSE 
Oral doses of verapamil are usually 80 - 120mg three times a day. For 
maintenance treatment with the slow-release preparations a twice daily dose of 
240 - 360 mg should be adequate. 
NIFEDIPINE 
MECHANISM OF ACTION 
Nifedipine has the greatest vasodilator effect of the calcium antagonists, but 
has minimal effect on conduction. It is a dihydropyridine calcium antagonist 
and inhibits the calcium channel by acting at a binding site different to that 
of verapamil. 
PHARMACOKINETICS : 
It is almost completely absorbed, but oral bioavailability is reduced to 60 -
75% by first-pass hepatic metabolism. The plasma T1; 2 is 2 - 6 hours. 
Hypotensive effects occur within 15 - 30 minutes after an oral dose and within 
2 - 3 minutes if the capsule is broken and the liquid contents swallowed. 
Nifedipine is completely metabolised in the liver, with 85% of the inactive 
metabolites being excreted in the urine. 
DOSE : 
In mild to moderate hypertension, the required dose as monotherapy is about 10 
- 20 mg three times a day. A starting dose of 5 mg should be used in the 
elderly to avoid possible cerebral underperfusion. 
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DILTIAZEM 
MECHANISM OF ACTION 
Diltiazem is a peripheral vasodilator, with mild negative inotropic effects 
(Buckley Met al, 1991). Its mechanism of action is similar to that of 
verapamil, but the reduction in blood pressure is usually accomplished without 
reflex tachycardia, probably due to its suppression of sinoatrial node 
stimulation. 
PHARMACOKINETICS : 
It is well absorbed, but due to first pass metabolism in the liver only 45% is 
bioavailable. The onset of action is within 15 - 30 minutes, but the maximum 
hypertensive effect occurs at 1 - 2 hours. The plasma T1; 2 is 2 - 11 hours, 
but averages 4.5 hours. Diltiazem is acetylated in the liver and eliminated 
by the kidneys (35%) and the GI tract (65%). 
DOSE : 
The usual initial dose is 60mg three to four times a day, increasing if 
necessary at one to two day intervals to 90 mg three or four times a day, to a 




MECHANISM OF ACTION : 
Its chemical structure similar to the thiazides and is best regarded as a 
thiazide-like diuretic. The primary antihypertensive action is thought to be 
due to inhibition of net inward flow of calcium, thereby inhibiting the 
resultant phasic contractions in vascular smooth muscle. 
PHARMACOKINETICS : 
Oral absorption is rapid and high and its duration of action is 16 - 36 hours 
and the terminal half life is 14 - 16 hours. Indapamide is extensively 
metabolised in the liver and its major route of excretion is the kidneys. 
ADVERSE EFFECTS : 
There is a low incidence of CNS side effects, e.g. headache, dizziness and 
lassitude. With long term use mild hypokalaemia may occur. 
DOSE : 
A single dose of 2.5mg in the morning is sufficient in 70 - 80% of patients 
with mild hypertension. 
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AGENTS ACTING ON RENIN-ANGIOTENSIN SYSTEM 
MECHANISM OF ACTION : 
ACE inhibitors appear to lower the blood pressure by a number of mechanisms. 
Firstly, angiotensin converting enzyme is responsible for converting 
angiotensin I to angiotensin II (a potent vasoconstrictor and stimulator of 
aldosterone secretion) and for the breakdown of bradykinin (a vasodilator). 
Secondly, specific vasodilation may enhance natriuresis and thirdly by 
preventing reabsorption of sodium by aldosterone to reduce natriuresis. 
Fourthly, they reduce the inactivation of vasodilatory bradykinins. The other 
mechanisms are the inhibition of local formation of angiotensin II in the 
vascular tissue and in the myocardium and by modulating the sympathetic 
nervous system pre- and post synaptically. This antisympathetic action of ACE 
inhibition also contributes to their antihypertensive effect. 
CAPTOPRIL 
PHARMACOKINETICS : 
About 60 - 75% is absorbed and the elimination T1; 2 is 2 - 3 hours but the 
duration of action is approximately 6 - 8 hours. Its antihypertensive effects 
may last for up to 12 hours. It is partly metabolised in the liver and 40 -
50% of the oral dose is excreted unchanged in the urine. 
ADVERSE EFFECTS : 
The most commonly occurring adverse effects are first dose hypotension, 
disturbances in taste, a dry hacking cough and skin rashes. Proteinuria and 
angioedema occur less frequently. 
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DOSE : 
Treatment is usually started with a dose of 6.25mg, which is then increased 
over several weeks to a maximum dose of 150 mg daily, given in 2 divided 
doses. 
ENALAPRIL 
Enalapril is de-esterified in the liver and the kidney to the active compound, 
enalaprilat (Opie, 1991). It is a more potent ACE inhibitor than captopril. 
PHARMACOKINETICS : 
About 55 - 75% of the oral dose is rapidly absorbed. The time to peak serum 
concentration is about 2 hours for enalapril and 5 hours for enalaprilat. 95% 
of either enalapril or enalaprilat is excreted via the kidneys. In 
hypertension the elimination T1/ 2 for enalaprilat is 4 - 5 hours, but 
increases to about 11 hours after multiple doses. 
ADVERSE EFFECTS : 
Without the SH group of captopril the immune-based toxic effects (neutropenia 
and proteinuria) are very rare. The other side effects of captopril are 
common to enalapril. Dizziness and headache are frequently and fatigue has 
also ben reported with enalapril. 
DOSE : 
Patients are usually started on a dose of 2.5 - 5 mg daily and this may then 
be increased to a dose of 10 - 20 mg as a single daily dose, however a twice 
daily dosage may also be given. 
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LISINOPRIL 
Lisinopril is a lysine derivative of enalaprilat and does not require 
hydrolysis to become active. Lisinopril also has a higher affinity for ACE 
than captopril. 
PHARMACOKINETICS : 
Lisinopril is slowly absorbed after an oral dose and its hypotensive effects 
start 2 hours after ingestion with peak at 4 to 8 hours. It is not metabolised 
and 30% is excreted unchanged by the kidneys and 60% in the faeces. The plasma 
T1; 2 is 12 - 14 hours, with a duration of action exceeding 24 hours. 
DOSE : 
The initial dose 2.5 to 5 mg with a maintenance dose of 20 mg as a single 
daily dose. 
RAMIPRIL 
Ramipril binds rapidly to form an initial enzyme-inhibitor complex which then 
slowly undergoes isomerisation to give complete inhibition. The subsequent low 
dissociation rate contributes to the high potency and long duration of action 
of the drug. 
PHARMACOKINETICS : 
Ramapril is rapidly hydrolysed in the liver to ramiprilat; some hydrolysis may 
occur across the intestinal wall. The kidneys are the main route of 
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elimination. The plasma T112 of ramiprilat is 1 - 4.5 hours with a mean of 3 
hours. 
DOSE : 
A starting dose of 2.5 mg daily is used and this is increased gradually over 1 
- 2 weeks to a dose of 5 - 10 mg daily. 
DIURETICS 
LOW-CEILING DIURETICS, THIAZIDES 
THIAZIDE DIURETICS 
MECHANISM OF ACTION : 
Thiazide diuretics are sulphonamide derivatives. Initially blood pressure is 
lowered by a combination of inhibition of sodium and chloride reabsorption in 
the early distal tubule and a direct effect of the drug on the vascular smooth 
muscle (Tarazi et al, 1970). The long term hypotensive effect is associated 
with a reduction in total peripheral resistance (Jackson, 1988). Excretion of 
potassium, magnesium and zinc is enhanced while calcium excretion is 
diminished. Low doses are used in the long term management of hypertension, 
high doses cause side effects (Briant RH, 1991). The dose response curve with 
respect to blood pressure is very flat, therefore increasing the dose beyond a 




The oral bioavailability is about 70% and the onset of diuretic action is 
within 2 hours and lasts for 6 - 12 hours, but the hypotensive effect may take 
3 - 4 days before becoming evident. Maximum blood pressure reduction occurs 
after about 8 weeks of therapy (Leary, 1989). Hydrochlorothiazides biological 
T1; 2 is up to 15 hours. Approximately 95% is excreted unchanged in the urine. 
ADVERSE EFFECTS : 
Hydrochlorthiazide may be associated with electrolyte imbalances including, 
hypokalaemia and hypomagnesaemia. Glucose tolerance may be reduced, diabetes 
precipitated and control with antidiabetic agents lost. Hyperuricaemia may 
precipitate gout. Blood liproproteins may be adversely affected, resulting in 
an increase in triglycerides and LDL and a decrease in HDL. 
DOSE : 
The dose is usually 12.5 - 25 mg daily, as a single morning dose is adequate 
for blood pressure control 
CYCLOPENTHIAZIDE 
PHARMACOKINETICS : 
Little is known about the extent of absorption, distribution and elimination 
half-life of cyclopenthiazide. Diuretic action occurs within 1 - 2 hours and 




A dose of 0.25mg as a single daily dose is used for hypertension. In South 
Africa cyclopenthiazide is only available in combination with potassium 
chloride. 
HIGH-CEILING DIURETICS, SULFONAMIDES 
FUROSEMIDE 
Furosemide is chemically similar to the thiazide diuretics (BMJ, 1986). 
Furosemide is a less potent antihypertensive agent than are the thiazide 
diuretics and is usually used in combination with other antihypertensive 
agents. Furosemide is mainly used where there is renal impairment and in 
patients with diabetes. 
PHARMACOKINETICS 
Approximately 60 70% of the oral dose is absorbed. Onset of action after an 
oral dose is within 30 - 60 minutes and lasts approximately 3 - 6 hours, but 
the maximum antihypertensive effect may only be evident after a few days. The 
plasma T112 is 1.5 hours, although this may be prolonged in renal or hepatic 
failure. 60 - 70% is excreted unchanged in the urine and the rest is 
metabolised in the liver. 
ADVERSE EFFECTS 
The most common adverse effects are fluid and electrolyte imbalances (e.g. 
hypokalaemia, hypomagnesaemia, hypocalcaemia and hypochloraemic alkalosis). 
Hearing impairment is associated with large doses, especially if combined with 
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other drugs with ototoxic potential. Sulphonamide-sensitive patients may 
develop allergic dermatologic and vasculitic reactions. 
DOSE : 




MECHANISM OF ACTION 
Spironalactone is a competitive inhibitor of aldosterone on the distal 
tubules. Its hypotensive mechanism is thought to be due to blocking the effect 
of aldosterone on arteriolar smooth muscle or by altering the extracellular-
intracellular sodium gradient. 
PHARMACOKINETICS 
About 70% of the oral dose is absorbed and is metabolised, by the liver, to 
canrenone, which is the major active metabolite (Goodman & Gilman, 1990). The 
plasma T1; 2 of canrenone is 10 - 35 hours. Spironolactone and canrenone are 
excreted predominantly by the kidneys. 
ADVERSE EFFECTS : 
The most serious side effect is hyperkalaemia as it can cause cardiac 
irregularities. This is more probable when used with potassium supplements or 
potassium-sparring agents or in patients with renal failure. Other effects are 
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anorexia, vomiting, abdominal cramps, diarrhoea, headache, drowsiness, 
deepening of the voice, hirsutism and confusion. 
DOSE : 
Spironalactone is usually used in a dose of 25 - 100mg daily. 
AMILORIDE/TRIAMTERENE 
MECHANISM OF ACTION : 
Amiloride and triamterene inhibit the sodium channel, which is concerned with 
sodium reabsorption in the distal tubule. They are weak diuretics when used 
alone, but also has some antihypertensive activity. When combined with another 
diuretic, this effect is additive. Both have potassium and magnesium-sparring 
. properties. 
PHARMACOKINETICS 
About 50% of the oral dose of amiloride and triamterene are absorbed. The 
onset of diuretic activity is within 2 hours and lasts for up to 24 hours with 
amiloride and 7 - 9 hours with triamterene. The T1; 2 of amiloride is 6 - 9 
hours. Amiloride is not metabolised and is eliminated unchanged by the kidneys 
whereas triamterene is extensively metabolised in the liver and excreted in 
the urine (Goodman & Gilman, 1990). 
ADVERSE EFFECTS : 
The most serious adverse effect is hyperkalaemia, but when combined with a 
thiazide diuretic this effect is less. Other effects are nausea, anorexia, 
abdominal pain and flatulence, headache, weakness and dizziness. 
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DOSE : 
Amiloride and triamterene are only available in South Africa in combination 
with hydrochlorthiazide. When combined with a thiazide diuretic a single daily 
dose of 2.5 - 5mg of amiloride and 25 - 50 mg of triamterene is used in the 
management of hypertension. 
BETA BLOCKING AGENTS, PLAIN 
MECHANISM OF ACTION : 
They competitively inhibit the action of catecholamines on beta 
adrenoreceptors (BMJ, 1984). Some block both 81 receptors (heart rate and 
contractility) and 82 receptors (vascular and bronchial smooth muscle), 
whereas others block mainly 81 receptors and are relatively cardioselective. 
They are thought to reduce the blood pressure by reducing the cardiac output. 
But with continued treatment cardiac output returns to normal while blood 
pressure remains low, owing to decreased peripheral vascular resistance 
(Katzung, 1989). 
BETA BLOCKING AGENTS, NON-SELECTIVE 
PROPRANOLOL 
PHARMACOKINETICS 
The oral bioavailability is low due to first-pass metabolism. Propranolol is 
lipid-soluble and readily passes across the blood brain barrier. The T1/ 2 is 3 
hours, but because propranolol is extensively metabolised in the liver to give 
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an active metabolite, 4-hydroxypropranolol, the effective half-life becomes 
much longer. 
ADVERSE EFFECTS 
The most common side effect is lethargy and a heavy feeling in the limbs 
(Burgess, 1991). Effects on the central nervous system can result in 
nightmares, sleep disturbances and even mild depression. Propranolol 
frequently causes bradycardia, dizziness, drowsiness, visual disturbances and 
hallucinations, confusion and mental depression . GI disturbances include 
nausea, vomiting, diarrhoea and constipation. Sexual dysfunction also occur. 
HDL lipoproteins are reduced while serum triglyceride levels are increased. 
DOSE : 
The usual starting dose of propranolol is 20 - 40mg twice daily and may be 
increased to a dose of 120 - 320mg/ day in 2 divided doses, although there is 
little additional antihypertensive effect above 80 mg per day. 
CARDIOSELECTIVE BETA BLOCKING AGENTS (C07AB) 
ATENOLOL 
PHARMACOKINETICS : 
50 - 60% of the oral dose is absorbed and the plasma T1; 2 is 6 - 7 hours, but 
the antihypertensive effect lasts up to 24 hours. Atenolol has poor lipid 
solubility and therefore does not readily cross the blood brain-barrier. 90% 
of an oral dose is excreted unchanged in the urine. 
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ADVERSE EFFECTS : 
The most troublesome of the symptomatic adverse effects are cold extremities 
and fatigue. 
DOSE : 
The usual dose for hypertension is 50 - 100mg, although atenolol has a flat 
dose response curve therefore doses above 50 mg daily have little value (BMJ, 
1986). 
METOPROLOL 
MECHANISM OF ACTION 
The mechanism of action of metoprolol is essentially the same as that of 
propranolol, except for the fact that metoprolol is less potent in blocking B2 
receptors (Katzung, 1989). 
PHARMACOKINETICS : 
Metoprolol is rapidly and almost completely absorbed after an oral dose. 
Bioavailability may be increased by food. The plasma T1; 2 is about 4 hours. 
About 50% of the drug appears to undergo first-pass metabolism in the liver 
and only about 10 % is eliminated unchanged in the urine. Metoprolol is 
rapidly and widely distributed in the body and readily crosses the blood-
brain barrier. 
DOSE : 
The starting dose of metoprolol is 25mg bd which may be increased slowly to a 
maintenance dose of 100 - 400 mg daily as a single or divided into a twice 




1. Amiloride Co. / Metformin and Chlorpropamide 
By raising blood sugar levels the thiazide diuretics and other 
related diuretics can reduce the effects of the hypoglycaemic 
agents and impair the control of diabetes. This effect is well 
documented but only of minor clinical significance. Concurrent use 
need not be avoided but the effects should be monitored. Some 
patients will require a modest increase in their dose. 
There is also a report of eight cases of hyponatraemia in patients 
on Moduretic (hydrochlorthiazide 50mg and amiloride 5mg) and 
chlorpropamide. This interaction is rare and of minor clinical 
importance (n=3; classified as a minor interaction). 
2. Amiloride Co. / Triamterene Co., Brinerdin and Rauwolfia Co. 
The concurrent use of two potassium sparing/ thiazide 
combinations is unnecessary and will lead to the potentiation of 
the undesirable effects of the thiazide diuretics (n=5; classified 
as increased side effects). 
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3. Amiloride Co. / Carbamazepine 
There are two reports of patients an thiazide diuretics who 
developed symptomatic hyponatraemia while on carbamazepine. 
Although both drugs can cause sodium loss from the body, one 
should be aware of the possible potentiation. The interaction is 
however uncommon and only of minor clinical importance (n=l; 
classified as a minor interaction). 
4. Amiloride Co., Thiazides and lndapamide / Indomethacin and 
Ibuprofen 
The antihypertensive effects of the thiazides and related 
diuretics can be reduced to some extent by indomethacin. The 
interaction appears to be of only moderate clinical significance 
and may possibly only be a transient effect. Ibuprofen appears to 
interact to a lesser extent or not at all. Concurrent use of the 
two drugs is not contra-indicated but the patient should be 
monitored and the thiazide dose adjusted if necessary 
(n=7; classified as a moderate interaction). 
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5. Methyldopa / Digoxin 
Methyldopa does not affect digoxin levels, but marked bradycardia 
has been observed in two elderly women when given both drugs. 
Concurrent use need not be avoided but the heart should be 
monitored for any slowing as this effect seems to be more than the 
sum of the two individual drugs (n=l; classified as a minor 
interaction). 
6. Methyldopa / Oxazepam 
This is in fact not a true interaction but more one of additive 
side effects. Concomitant use of the two drugs could lead to 
additive depressant effects on the central nervous system e.g. 
sedation (n=l; classified as increased side effects). 
7. Methyldopa / Phenobarb 
The effects of methyldopa are not altered by the use of 
phenobarbitone, but once again the central nervous system side 
effects of each of the drugs will be exacerbated when used 
together (n=l; classified as increased side effects). 
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8. Rauwolfia Co. / Methyldopa 
Concurrent use of these two drugs will lead to the additive of 
both of their side effects such as, nasal congestion and 
sedation(n=l; classified as increased side effects). 
9. Rauwolfia Co. / Phenytoin 
Concurrent use of these two agents could result in the additive 
effects of the individual agents side effects such as, drowsiness 
and depression (n=l; classified as increased side effects). 
10. Reserpine/ Tricyclic Antidepressants 
Rauwolfia alkaloids cause depression and sedation and are 
therefore not usually used in patients needing treatment for 
depression (n=l; classified as a moderate interaction). 
11. Beta-blockers/ Alpha-blockers 
Prazosin causes some patients to experience acute postural 
hypotension, tachycardia and palpitations when they first start 
treatment. Postural hypotension is more likely to occur if the 
patient is already taking a beta-blocker. Concurrent use need not 
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be avoided, but in order to avoid postural hypotension, it has 
been recommended that patients already taking beta-blockers should 
start on a low dose of prazosin (n=l; classified as increased side 
effects). 
12. Beta-blockers/ Indomethacin and other NSAIDs 
Indomethacin reduces the antihypertensive effects of the beta-
blockers. This interaction can be accommodated either by raising 
the dosage of the beta-blocker or by using a non interactive 
NSAID. The concurrent use of indomethacin need not be avoided but 
one should anticipate the need to increase the dosage of the beta-
blocker. Alternatively exchange the indomethacin with a non-
interacting NSAID. Imidazole salicylates, naproxen, ibuprofen and 
sulindac interact minimally or not at all (n=2; classified as a 
minor interaction). 
13. Diltiazem / Nifedipine 
A reduction in the metabolism of the nifedipine by diltiazem has 
been suggested, although the information is limited and the 
clinical importance is uncertain 
(n=l; classified as increased side effects). 
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14. Verapamil / Digoxin 
The Digoxin-Verapamil interaction is well established and occurs 
in most patients. Serum digoxin levels should be well monitored 
and downward adjustments made to avoid digoxin toxicity. A 30 -
50% dosage reduction is recommended. The magnitude of the increase 
is digoxin levels is dose dependant with a significant increase if 
the verapamil dosage is increased from 160mg to 240mg daily (n=l; 
classified as a moderate interaction). 
15. ACE Inhibitors/ Oral Hypoglycaemics 
Hypoglycaemia has been seen in a few diabetics treated with 
Captopr;l and Enalapr;1. Concurrent use need not be avoided but it 
would be prudent to warn patients that excessive hypoglycaemia has 
occurred and it may therefor~necessary to modify the dosage of the 
oral hypoglycaemic agent (n=2; classified as a minor interaction). 
16. ACE Inhibitors/ Amiloride Co., Triamterene Co. and Thiazide 
Diuretics 
Normally the concurrent use of diuretics and ACE inhibitors is 
safe and effective but hypotensive symptoms occasionally occur. 
Potassium sparing diuretics such as amiloride, triamterene or 
potassium supplements can result in hyperkalaemia and should not 
195 
be used in conjunction with ACE inhibitors unless the serum 
potassium levels can be monitored, although there is some evidence 
to suggest that this effect is less marked with Enalapr;l than 
with Captoprjl (n=B; classified as a minor interaction). 
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APPENDIX VII 
THE PRICE OF DRUGS IN THE PUBLIC AND PRIVATE SECTORS 
SINGLE DRUGS 
GENERIC NAME PRICE (in cents/tablet) 
PUBLIC PRIVATE 
Atenolol 50 mg 12.9 116.9 
100 mg 22.4 179.2 
Captopril 25 mg 30.3 192.5 
50 mg 67.7 315.9 
Diltiazem 60 mg 43.0 184.3 
90 mg 56.4 304.0 
Enalapril 5 mg 32.2 199.7 
10 mg 58.9 281. 7 
20 mg 135.5 410.6 
Furosemide 40 mg 2.3 35.0 
Hydralazine 25 mg 2.2 42.5 
Hydrochlorothiazide 25 mg 1. 2 54.1 
Indapamide 2.5 mg 13.5 215.9 
Lisinopril 5mg not available 175.1 
10mg not available 246.8 
20 mg not available 410.6 
Methyldopa 250 mg 8.9 39.0 
Metoprolol 100 mg 36.0 269.8 
Nifedipine 10 mg 19.6 96.8 
Prazosin 1 mg 8.2 59.9 
2 mg 14.0 100.2 
5 mg 31. 2 238.9 
Propranolol 40 mg 1. 8 41. 6 
Ramipril 2.5 mg 27.4 208.4 
5 mg 54.9 310.9 
Reserpine 0.25 mg 1.1 3.3 
Spironolactone 25 mg 5.3 48.8 
Verapamil 40 mg 4.0 58.8 
80 mg 7.1 84 





Spironalactone 25 mg 
IsobutylHCTZ 2.5 mg 
PRICE (in cents/tablet) 
PUBLIC PRIVATE 
not available 175.7 
Brinerdin R 18.3 321. 8 
Dihydroergocristine 0.5 mg 
Clopamide 5 mg 
Reserpine 0.1 mg 
Co-reitec R not available 
Enalapril 20 mg 
Hydrochlorothiazide 12.5 mg 
Dyazide R 
Triamterene 50 mg 
Hydrochlorothiazide 25 mg 
Moduretic R 
Amiloride 5 mg 
Hydrochlorothiazide 50 mg 
Navidrex - K R 
Cyclopenthiazide 0.25 mg 
KCL 600 mg 
Protensin- MR 
Hydroflumethiazide 50 mg 
Reserpine 0.125mg 
Rautrax -25 R 
Hydroflumetiazide 25 mg 
Rauwolfia serpentina 50 mg 
KCL 625 mg 
Urex - KR 
Hydrochlorothiazide 50 mg 
KCL 300 mg 
7 .1 
2.4 
4.8 
not available 
9.8 
not available 
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533.3 
67.0 
52.7 
105.3 
62.6 
90.9 
29.4 
